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Abstract 
The ubiquitin-proteasome pathway is the major pathway of selective protein degradation 
in the cell. Disruption of this pathway affects cellular protein homeostasis and contributes to 
diseases like cancer, and neurodegeneration.  The end point of this pathway is the proteasome, a 
complex protease formed by 66 polypeptides.  Structurally, it can be subdivided into the Core 
Particle (CP) and the Regulatory Particle (RP).   The CP harbors the proteolytic sites, whereas, 
the RP contains six orthologous AAA-ATPases, the Rpt proteins.  These Rpt’s are essential for 
proteasome function and are at the interface between RP and CP. The work in this thesis focuses 
on the Rpt subunit Rpt5 from yeast. The C-terminal tail of Rpt5 has been shown to contribute to 
the binding with the CP. However, our study showed it is also essential for the interaction with 
Nas2, one of nine proteasome-specific chaperones.  Thus, Nas2 might function as a regulator of 
the Rpt5-CP interaction. Further analyses suggested that Nas2 has an additional function in 
assembly, and that mutating the tail of Rpt5 results in increased binding of the proteasome-
associated protein Ecm29 to the proteasome. We showed that Ecm29 binds Rpt5 directly, 
thereby inducing a closed conformation of the CP substrate entry channel, and inhibiting 
proteasomal ATPase activity. Consistent with these activities, several proteasome mutant strains 
showed Ecm29-dependent accumulation of unstable substrates. Thus, Ecm29 is an inhibitor of 
the proteasome in vivo and in vitro. Interestingly, besides the Rpt5 mutants, several other 
proteasome mutants show increased levels of Ecm29, suggesting Ecm29 has a role in quality 
control. Consistent with this, we observed that Ecm29 associates preferably with specific 
mutants and nucleotide-depleted proteasomes.  
Based on our data we propose a model, where early in assembly Nas2 binds to the Rpt5 
tail inhibiting the Rpt5-CP interaction directly.  Later in assembly Ecm29 performs a quality 
control function, where it recognizes and remains bound to defective proteasomes.  By inhibiting 
these proteasomes Ecm29 prevents the aberrant degradation of proteins.  
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 Abstract 
The ubiquitin-proteasome pathway is the major pathway of selective protein degradation 
in the cell. Disruption of this pathway affects cellular protein homeostasis and contributes to 
diseases like cancer, and neurodegeneration.  The end point of this pathway is the proteasome, a 
complex protease formed by 66 polypeptides.  Structurally, it can be subdivided into the Core 
Particle (CP) and the Regulatory Particle (RP).   The CP harbors the proteolytic sites, whereas, 
the RP contains six orthologous AAA-ATPases, the Rpt proteins.  These Rpt’s are essential for 
proteasome function and are at the interface between RP and CP. The work in this thesis focuses 
on the Rpt subunit Rpt5 from yeast. The C-terminal tail of Rpt5 has been shown to contribute to 
the binding with the CP. However, our study showed it is also essential for the interaction with 
Nas2, one of nine proteasome-specific chaperones.  Thus, Nas2 might function as a regulator of 
the Rpt5-CP interaction. Further analyses suggested that Nas2 has an additional function in 
assembly, and that mutating the tail of Rpt5 results in increased binding of the proteasome-
associated protein Ecm29 to the proteasome. We showed that Ecm29 binds Rpt5 directly, 
thereby inducing a closed conformation of the CP substrate entry channel, and inhibiting 
proteasomal ATPase activity. Consistent with these activities, several proteasome mutant strains 
showed Ecm29-dependent accumulation of unstable substrates. Thus, Ecm29 is an inhibitor of 
the proteasome in vivo and in vitro. Interestingly, besides the Rpt5 mutants, several other 
proteasome mutants show increased levels of Ecm29, suggesting Ecm29 has a role in quality 
control. Consistent with this, we observed that Ecm29 associates preferably with specific 
mutants and nucleotide-depleted proteasomes.  
Based on our data we propose a model, where early in assembly Nas2 binds to the Rpt5 
tail inhibiting the Rpt5-CP interaction directly.  Later in assembly Ecm29 performs a quality 
control function, where it recognizes and remains bound to defective proteasomes.  By inhibiting 
these proteasomes Ecm29 prevents the aberrant degradation of proteins.  
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Chapter 1 - Introduction 
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 Protein homeostasis 
For cellular proteins the levels inside the cell are determined both by the rate of protein 
synthesis and the rate of degradation.  In the cell this is controlled by a network of pathways that 
tightly regulate the synthesis, folding, transport and degradation of proteins, known as protein 
homeostasis or proteostasis (Fig. 1.1).  Maintenance of proteostasis is vital for cell function and 
ensures an organism will have successful development, healthy aging, the ability to resist 
environmental stress, and minimimal disruptions by pathogens. The loss of proteostatic control 
can lead to the accumulation and aggregation of misfolded proteins, or to the untimely 
degradation of proteins (1).  These features are associated with numerous conditions including 
metabolic diseases, cancer and neurodegenerative disorders (15, 36).  
The key to protein homeostasis is the balance between pathways involved in synthesis, 
post-translational modifications, and the degradation of proteins.  
 
 
 
Figure 1.1  Cellular pathways essential to achieving homeostasis. 
 
All cellular proteins are subjected to quality control mechanisms throughout their lifetime 
inside the cell (15, 21). Once proteins are synthesized at the ribosome, they need to acquire their 
tertiary (or quaternary) structure to be functional.  Protein folding in vivo is accomplished 
through intrinsic factors of the folding polypeptide chain, often with the assistance of multiple 
classes of chaperones (1, 35).  Different conditions can lead to protein degradation: abnormally 
synthesized proteins; de novo synthesized proteins that fail to spontaneously fold, or can’t attain 
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their rightful conformation with the assistance of chaperones; previously folded proteins that 
unfold due to undesired post-translational modifications. Under such conditions proteins are 
delivered to the proteolytic machinery for degradation (15, 21). 
Additionally, proteins could be targeted for degradation when they are present in excess 
(e.g. a protein that is part of a multimeric complex and is overexpressed will be unstable due to 
the inability to interact with a binding partner or chaperone); when the cell is going through 
different stages of the cell cycle; or when the cell requires changing its internal environment in 
response to external conditions (e.g. temperature, ion concentrations, pH) (19). 
In all, there are multiple mechanisms involved in keeping proper protein homeostasis 
within the cell, including the degradation of proteins. 
 Protein degradation 
Based on their turnover rate proteins can be classified as either “short-lived” proteins 
(with a fast degradation rate), or “long-lived” proteins (with a much slower degradation rate).  
Early studies that monitored protein kinetics together with lysosome inhibitors, suggested that 
long-lived and short-lived proteins were degraded differentially by either one of the two major 
pathways of protein degradation in the cell, the autophagy-lysosomal system (ALS) and the 
ubiquitin-proteasome system (UPS), respectively (4, 7).  The assumption was that proteasome-
mediated degradation had a high degree of specificity, because it involved specific labeling of 
substrates through the process of ubiquitination; whereas lysosomal degradation was non-
selective in nature. However, more recent studies have shown that there is more complexity to 
these systems, and one has to consider not only the selectivity, and degradation kinetics, but also 
the purpose served by the degradation of the proteins (e.g. clearance, recycling) (7).   
Figure 1.2 gives a general overview of how proteins are sorted for degradation. The UPS 
degrades two types of proteins: Fully functional proteins that are degraded as part of a regulatory 
mechanism (e.g. proteins involved in cell division, signal transduction) (11); and non-functional 
misfolded proteins that are degraded as part of a clearance mechanism (e.g. proteins degraded 
through the ER-associated degradation pathway (ERAD)) (12).  Many short-lived proteins are 
degraded by the UPS.  The proteolytic activity of the proteasome is not very specific, as it can 
degrade almost any protein.  The specificity is achieved by selectively targeting substrates to the 
proteasome, this is done by labeling substrates through the covalent attachment of ubiquitin.  
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Thus, labeling with ubiquitin determines the specificity (4). There is one known exception to this 
rule, ornithine decarboxylase, a short-lived protein that is degraded by the proteasome without 
getting ubiquitinated.  
 
 
Figure 1.2 Sorting of proteins to be degraded in the cell 
 
Proteins degraded by the ALS can be divided in two groups: First, proteins that are 
degraded in-bulk (e.g. during nutrient deprivation), as part of a nutrient recycling mechanism.  
The proteins that are degraded during this process would be functional proteins that are relatively 
long-lived (14, 18).  This “in-bulk” degradation even includes whole organelles, and 
phagocytosed microbes (5); the second group of proteins that can be degraded by the ALS are 
non-functional misfolded proteins, these proteins are degraded as part of a clearance mechanism.  
The removal of these proteins requires a higher level of specificity. These proteins would likely 
be short-lived monomeric proteins that could turn long-lived due to aggregation (7). 
 The autophagy-lysosome system 
Substrates of the ALS can be intra- and extracellular components. These substrates are 
degraded in an organelle known as the lysosome. The lysosome has an acidic lumen, and is 
limited by a single-lipid bilayer membrane.  It contains 60 different types of acidic hydrolases 
that are devoted to the degradation of substrates. The hydrolases are activated by the acidic pH of 
the lumen, and can degrade a vast repertoire of biological substrates, including proteins, 
carbohydrates and DNA.  Thus, the degradation is largely determined by what gets targeted to 
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the lysosome, and not by the enzyme specificity within the lysosome. Extracellular material that 
is destined for degradation reaches the lysosome mainly through the endocytic pathway, whereas 
intracellular components are transported to the lysosome by autophagy (28). 
Autophagy is characterized by the formation of double-membrane vesicles called 
autophagosomes, which sequester the cytoplasmic structures destined for destruction.  Three 
different forms of autophagy have been described: macroautophagy, microautophagy, and 
chaperone-mediated autophagy (CMA).  They all differ in their mechanisms, and functions.  (3, 
23).  
Both micro- and macroautophagy have the capacity to engulf large structures through 
both selective, and non-selective mechanisms, while CMA degrades only soluble proteins in a 
selective manner.  A general overview of the three different types of autophagy is depicted in 
Figure 1.3. 
Microautophay consists in the direct sequestration of cytosolic components by the 
lysosome. In microautophagy, the lysosomal/vacuolar membrane is randomly invaginated and 
differentiated to enclose portions of the cytosol. The formed vesicles are fused homotypically, 
and then bud into the lumen.  The process has been well described in yeast.  Two Atg7-
dependent ubiquitin-like conjugation systems participate in microautophagy, mediating 
membrane tethering and vesicle fusion (20). The function and relevance of microautophagy in 
higher eukaryotes is not clear. 
In macroautophagy, the cargo is sequestered within a unique double-membrane cytosolic 
vesicle called the autophagosome.  Engulfment of the cargo can be either non-specific (bulk 
cytoplasm), or selective, targeting specific cargoes like organelles (ribophagy, mitophagy, etc.) 
(6).  The autophagosome is a double-membrane vesicle, which captures cytosolic proteins and 
organelles during its transformation from a planar membrane disk into a sphere.  The signals that 
trigger the formation of the autophagosome and the origin of the membrane are still under debate 
(8, 34), with evidence suggesting the ER, golgi and mitchondria can be providers of membrane 
for the autophagosome (10, 22).  The autophagosome fuses with an endosome or a lysosome, 
where it acquires hydrolases.  Lysis of the autophagosome inner membrane and breakdown of 
the contents occurs in the lysosome.  The resulting breakdown products are released back into 
the cytosol, through amino acid transporters, to generate new cellular components and energy (6, 
9, 27). 
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Figure 1.3  The different types of autophagy. 
a. Macroautophagy, proteins are sequestered along with other cytosolic components and 
organeles by a de novo-formed isolation membrane that expands and seals to form a double-
membane vesicle, the autophagosome. Degradation occurs when autophagosomes fuse with the 
lyosome. Selective variations of this process, in which distinct substrates (aggregate protein or 
organelles) are targeted for degradation, and their names, are also depicted.                b. 
Micoautophagy, invaginations at the surface of the lysosome or late endosomes trap cytosolic 
material, including proteins, and are then internalized after membrane scission and degraded in 
the lumen of the organelle. Cytosolic material can be sequestered 'in bulk' or selectively with the 
help of a cytosolic chaperone that recognizes the substrates. c. Chaperone-mediated autophagy, 
soluble cytosolic proteins containing a targeting motif are recognized by the cytosolic heat shock 
cognate 70 (HSC70) chaperone and its co-chaperones, which deliver the substrate to the 
membrane of the lysosome. After docking onto the cytosolic tail of the lysosomal receptor, the 
substrate protein unfolds and crosses the lysosomal membrane through a multimeric complex. 
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Substrate translocation requires a lumenal HSC70 chaperone and is followed by rapid 
degradation in the lysosomal lumen (Adapted from (6)). 
 
 
Finally, the third type of autophagy is chaperone-mediated autophagy (CMA).  It 
involves the direct translocation of unfolded substrate proteins across the lysosome membrane 
through the action of a cytosolic form of the chaperone Hsc70, which recognizes a KFERQ-like 
peptide sequence in the substrate protein, where it binds.  The chaperone-substrate complex then 
binds to the cytosolic tail of the membrane receptor LAMP-2A (lysosome-associated membrane 
protein type 2A), this binding induces the organization of the receptor into a multimeric 
complex. The substrate protein unfolds, and crosses the membrane through the translocation 
complex.  A luminal form of the chaperone Hsc70 assists in the translocation of the substrate (6, 
23). 
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 The Ubiquitin-proteasome system 
The ubiquiquitin-proteasome system degrades proteins in a two-step process.  During the 
first step, proteins are marked for degradation by covalent attachment of multiple ubiquitin 
molecules.  The resulting polyubiquitin chain serves as a marker for recognition by the 26S 
proteasome.  In the second step, the 26S complex recognizes the ubiquitinated-protein and 
degrades it. 
 
                    
Figure 1.4 The ubiquitin-proteasome system. 
During the ubiquitination process E1 binds to ubiquitin by consumption of one ATP to AMP in 
order to activate it. The ubiquitin-carrier enzyme E2 takes over the ubiquitin from E1. E2 
transfers the ubiquitin to a protein substrate bound to the ubiquitin ligase, E3. The ubiquitin 
chain is extended. The ubiquitinated binds to the 26 S proteasome in order to be degraded.  
 
 
 
Ubiquitin is a small protein composed of 76 amino acids. It is only found in eukaryotes, 
and is highly conserved from yeast to humans. It is a heat-stable protein that folds up into a 
compact globular structure. It is found throughout the cell (ubiquitous) and can exist either in 
free form or as part of a complex with other proteins. In the latter case, ubiquitin is conjugated to 
proteins through a covalent bond between the glycine at the C-terminal end of the ubiquitin 
molecule, and a lysine on the target protein. Conjugation of ubiquitin requires ATP hydrolysis, 
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and it can be attached as a single molecule (mono-ubiquitin) or as a chain of ubiquitin molecules 
(the more common form). To form chains, the ubiquitin molecules can attach to one another 
through seven lysine residues in positions 6, 11, 27, 29, 33, 48, and 63. The different forms of 
chains are named by which of the seven lysine amino acids in the ubiquitin molecule are used to 
link the chain together (17). Lysine 48-linked chains, linked by the 48th amino acid (a lysine) are 
the most common. They are the forms of chains that target proteins to the proteasome to be 
degraded (16). Lysine 63-linked chains, linked by the 63rd amino acid of ubiquitin (a lysine), 
regulate processes such as endocytic trafficking, inflammation, translation and DNA repair (30).  
The conjugation of ubiquitin happens via a three-step cascade of reactions (Fig 1.4).  
First, the ubiquitin-activating enzyme (E1), activates ubiquitin in a reaction that requires ATP.  
Then one of several ubiquitin-conjugating enzyme (E2), transfer the activated ubiquitin to the 
substrate, which is bound to a member of the ubiquitin-protein ligase family (E3).  The E3s 
catalyze the last step in the conjugation process, the covalent attachment of ubiquitin to the 
substrate.   
Ubiquitin can be removed from substrate proteins by the action of deubiquitinating 
enzymes (DUBs). These are cysteine-proteases that cleave the amide bond between the two 
proteins. DUBs are highly specific, with only a few substrates per enzyme. DUBs have 
additional roles within the cell besides removing ubiquitin from substrate proteins. Ubiquitin is 
either expressed as one polypeptide with multiple copies in a row or a polypeptide with one 
ubiquitin fused to specific ribosomal subunits. Certain DUBs cleave these proteins to produce 
active monoubiquitin. Additionally, monoubiquitin is formed by DUBs that cleave ubiquitin 
from free polyubiquitin chains that have been previously removed from proteins (25, 26). 
 
 The Proteasome 
The proteasome is a 66-polypeptide protease, which is structurally subdivided into the 
core particle (CP) and the regulatory particle (RP) (Fig 1.5).  The proteolytically active sites 
reside within the 20S CP, a cylindrically shaped structure formed by four stacked rings, ordered 
α1-7, β1-7, β1-7, α1-7. Subunits β2, β5, and β1 have proteolytic activity, displaying trypsin-like, 
chymotrypsin-like, and caspase-like peptidase activity respectively. The proteolytic active sites 
are sequestered within the CP chamber, which is important to protect the cell from nonspecific 
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degradation. The N-termini of the α-subunits close the ends of the cylinder, often referred to as 
the gate. The CP can degrade some proteins, however, most proteasomal protein degradation 
depends on ATP (2). The only ATP hydrolyzing proteins in the proteasome are six AAA-
ATPases located in the RP.  These proteins form a ring that converts the chemical energy from 
ATP hydrolysis into a mechanical force. This force is used to unfold substrates, thereby allowing 
a polypeptide end or interior loop to be translocated into the central chamber of the CP (33).  The 
19 subunits of the RP are divided between two sub-structures, the base and lid complexes. The 
lid contains the Rpn11 subunit that has deubiquitinating activity. The base contains the afore 
mentioned AAA-ATPases. The C-termini of these ATPases dock into pockets present between 
the α-subunits of the CP (29). This results in a translocation of the α tails and an opening of the 
gate. The CP can associate with one or two RPs, but there are other activators that could also 
bind to the 20S CP particle. These are Blm10/PA200 protein, a large HEAT-repeat containing 
protein, and the 11S/PA28 complex, a heteroheptamer.  Both activators can dock directly into the 
CP at the exclusion of the RP. 
 Assembly of the proteasome 
Assembly of the 26S proteasome is not a simple process, there are at least 66 proteins 
that need to come together, each occupying a single, defined site within the final structure. There 
are at least nine dedicated chaperones that assist in assembly of the proteasome (Table 1.1).  As 
expected from a chaperone, these molecules do not form part of the final biological functional 
complex.  Five of these chaperones assist in assembly of the CP, and four are dedicated to RP 
assembly. 
Four CP-chaperones play a role in assembly of the α-ring; yeast Pba (proteasome 
biogenesis associated protein) 1–4 or their probable orthologs in human PAC (proteasome 
assembly chaperone) 1–4. The assembly process seems largely conserved between yeast and 
humans. The proteins function as heterodimers: PAC1-PAC2 and PAC3-PAC4. The PAC3-
PAC4 heterodimer is probably important early in assembly, when it attaches to α5 and assists in 
the recruitment and ordering of additional α-subunits. Once α-ring assembly is completed, the β-
subunits are incorporated. Incorporation of the β-subunits requires dissociation of the PAC3-
PAC4 heterodimer. The PAC1-PAC2 heterodimer also assists in the formation of the α-ring, but 
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unlike PAC3-PAC4 it remains associated with the complex upon incorporation of the β-subunits 
(2).  
The fifth CP-chaperone Ump1, which has no role in α-ring formation, seems to function 
as a quality control agent. The Ump1 protein prevents stable dimerization of two half CPs until 
all seven β-subunits are assembled on the α-ring (creating the half CP). The formation of CP by 
two half CPs is accompanied by the maturation of the β-subunits and the degradation of Ump1 
and PAC 1-PAC2 (24).  
 
 
Figure 1.5 Proteasome structure 
The proteasome is formed by two RPs abutting a cylindrically shaped CP. The CP is formed by 
two α-rings and two β-rings. The RP consists of a base complex and a lid complex. Rpn10 is at 
the interface between these complexes (shown in light blue). The lid (green) contains indicated 
subunits and its function is not well understood, with the exception of rpn11, which functions as 
a deubiquitinating enzyme. The base contains a ring formed by six AAA-ATPases, Rpt1–6 
(purple ring), and the subunits Rpn1, Rpn2 and Rpn13 (shown as an orange box; see text for 
more details). The proteasome contains three heteromeric ring structures, each present twice. 
The α- and β-ring are formed by seven subunits; scissors indicate the active sites and the dots in 
the α ring show the binding pockets for the Rpt tails (see text). The pocket between α7 and α1 
lacks a Lys typically found in the pocket and might not harbour an Rpt C-terminus. The Rpt-ring 
is formed by six AAA-ATPases (2) (Adapted from (2)). 
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The RP (19S) can be divided into two subcomplexes, the base and lid. In yeast, these 
subcomplexes assemble independent of each other.   There are four RP dedicated chaperones that 
assist in assembly of the base (33).  The base is composed of six related AAA + ATPase, Rpt1–
Rpt6, and three non-ATPase subunits, Rpn1, Rpn2, and Rpn13 (Fig. 5). The six ATPase subunits 
are thought to form a ring structure that binds on the α-rings of the CP (Fig. 5). The chaperones 
involvd in RP assembly are Nas2/p27, Nas6/ gankyrin/p28, Rpn14/PAAF1, and Hsm3/S5b. 
Similarly to the CP chaperones they are not present in the mature 26S proteasome, and are 
evolutionarily conserved form yeast to humans (2, 24).  
 
Table 1.1 Proteasome assembly chaperones 
 Saccharomyces cerevisiae Homo sapiens 
Core Particle 
chaperones 
Pba1 PAC1 
Pba2 PAC2 
Pba3 PAC3 
Pba4 PAC4 
Ump1 UMP1 
Regulatory 
Particle 
chaperones 
Hsm3 S5b 
Nas2 P27 
Nas6 Gankyrin 
Rpn14 PAAF1 
 
The four RP chaperones are structurally distinct but contain domains involved in protein–
protein interactions: Nas2 has a PDZ domain, Nas6 has ankyrin repeats, Rpn14 has WD40 
repeats, and Hsm3 is composed of HEAT repeats (fig 6).  Interestingly, they all interact with the 
C-terminal tail of a specific Rpt subunit; Nas2 binds the C-terminal tail of Rpt5, Nas6 binds that 
of Rpt3, Rpn14 binds that of Rpt6, and Hsm3 binds that of Rpt1. Since the C-termini of Rpt 
subunits are necessary for docking onto the CP, it is probable that the base chaperones function 
to prevent premature binding of the Rpt subunits to the CP (2).  
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The RP lid consists of nine subunits, Rpn3, 5, 6, 7, 8 9, 11,12, and 15 (Sem1).  Recent 
studies into the mechanisms of assembly of the lid have revealed that lid assembly does not 
require chaperones in vitro, and is likely to be independent of chaperones in vivo as well (32). 
 
Figure 1.6 Domain topology of RP chaperones. 
The RP chaperones bind to the C-terminal of their respective RP subunit. However, they are very 
different structurally (2). 
 
In addition to the chaperones that assist in assembly, there are multiple proteins that 
associate with the proteasome.  Table 2 provides an example of some of these proteins and their 
proposed function.  Some of these proteins affect the substrate to be degraded, like Hul5 
(ubiquitin ligase) and Ubp6 (DUB).  Others have a broader range of functions, e.g. Blm10, which 
has been proposed to be involved in proteasome maturation, as well as to function as an activator 
of the proteasome (31).  Another protasome-associated protein with a wide range of proposed 
functions is Ecm29.  This 210 kD protein has been proposed to stabilize the proteasome, to 
remodel the proteasomes upon stress, and to work as a quality control factor of proteasome 
assembly.  Together with the chaperones these proteasome-associated proteins provide additional 
control elements to proteasome assembly and function.  
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Table 1.2  Examples of proteasome-associated proteins and their functions 
Protein Proposed Function 
Blm10 Proteasome maturation and DNA repair 
Ecm29 RP-CP stabilization, quality control of proteasome assembly 
Hul5 Ubiquitin-protein ligase 
Ubp6 Deubiquiinating enzyme, proteasome inhibitor 
Rad23 Delivers conjugates to proteasome 
 
The existence of nine chaperones and a proposed quality control factor, suggests that the 
assembly of the proteasome is an error prone process. Therefore, understanding how the cell 
achieves efficient assembly of the proteasome requires a detailed understanding of the function 
of the individual chaperones that guide this process. While the interaction of three RP 
chaperones (Nas6, Hsm3, and Rpn14) with their respective RP subunits was previously 
elucidated, our understanding of Nas2 has been more limited. In vitro studies showed that the 
chaperones bind to a specific Rpt protein through their C-terminal domains. However, this 
interaction did not involve the residues at the C-terminal tail. These tail residues are known to 
directly interact with the CP. We hypothesized that Nas2 does require these tail residues to 
interact with Rpt5 and the work described in the second chapter of this thesis, shows that the 
interaction between Nas2 and Rpt5 happens through the C-terminal tail of Rpt5.  The interaction 
requires the last three amino acids of the tail, suggesting that the binding of Nas2 prevents the 
docking of Rpt5 into the core particle.  This not withstanding, our work indicates that Nas2 has 
cellular functions beyond this ability to block Rpt5 from docking onto CP. Furthermore, we 
observed an accumulation of Ecm29 on proteasome mutants in these studies, and this forms the 
focus of chapter 3. 
 
The third chapter asks how is Ecm29 enriched in these mutants, and what it’s doing to 
the proteasome.  We found that Ecm29 preferentially binds to mutant or ATP-depleted 
proteasomes, and when it binds it inhibits proteasome function.  Ecm29 binds to Rpt5 
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inhibiting ATPase activity, which in part contributes to the defect in degradation exhibited by 
these proteasomes.  These suggest the existence of an additional quality control layer in 
proteasome assembly and function.  Overall, our studies provide further understanding of the 
mechanisms of assembly and quality control of the proteasome.   
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 Abstract 
The proteasome is a large and complex protease formed by 66 polypeptides. The 
assembly of the proteasome is assisted by at least nine chaperones. One of these chaperones, 
Nas2/p27, binds to the C-terminal region of the AAA-ATPase Rpt5. We report here that the tail 
of Rpt5 provides two functions. First, it facilitates the previously reported interaction with the 
proteasome core particle (CP).  Second, it is essential for the interaction with Nas2. Deletion of 
the C-terminal amino acid of Rpt5 disrupts the CP interaction, but not the binding to Nas2. The 
later is surprising considering Nas2 contains a PDZ domain, which is often involved in binding 
to C-termini.  Interestingly, deletion of the last three amino acids interferes with both functions. 
The disruption of the Rpt5-CP interactions gave distinct phenotypes different from disruption of 
the Nas2-Rpt5 interaction.  Additinally, proteasomes purified from a Saccharomyces Cerevisiae 
rpt5-Δ3 strain show a strong enrichment of Ecm29. The function of Ecm29, a proteasome 
associated protein, is not well understood. Our data show that Ecm29 can inhibit proteasomes, as 
our Ecm29 containing proteasomes have reduced suc-LLVY-AMC hydrolytic activity. 
Consistent with this apparent role as negative regulator, the deletion of ECM29 rescues the 
phenotypes of rpt5-Δ3 and nas2Δ in an hsm3Δ background. In sum, the interactions facilitated 
by the tail of Rpt5 act synergistically to minimize the formation of faulty proteasomes, thereby 
preventing recognition and inhibition by Ecm29. 
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 Introduction 
The proteasome is a large and complex molecular machine. It is responsible for the ATP 
dependent degradation of the majority of soluble cellular proteins destined for degradation in 
eukaryotic cells. It can biochemically be divided in two major subcomplexes, the core particle 
(CP) and the regulatory particle (RP). The CP is formed by four stacked rings, each consisting of 
seven subunits. The middle rings are formed by beta subunits and the outer rings by alpha 
subunits, creating an 1-7-1-7-1-7-1-7 structure. The proteolytic active sites are located on the 
inner surface of this hollow cylinder (1). The degradation of substrates requires the opening of a 
gate located at either end of the CP. This gate can be opened by activators such as the RP (1,2). 
The degradation of folded proteins generally requires the presence of the RP. RP is a 19 subunit 
complex that contains six AAA-ATPases. These ATPases form a ring where each subunit 
occupies a specific position (3,4). They are important for unfolding substrates, opening the gate 
of the CP, and substrate entry into the CP. At the outer surface of the CP surrounding the gate are 
seven pockets, each located at the interface between the α subunits. A number of these pockets 
can receive the C-terminal amino acids (“tails”) of presumably specific AAA-ATPases (5-7). 
However, the positioning of the ATPase ring in respect to the CP α-ring is still unclear (3,5,7,8). 
Docking of the tail of two different AAA-ATPases, namely Rpt2 and Rpt5, can result in opening 
of the gate (5,6). The tails of Rpt4 and Rpt6 play an important role in the assembly of the 
proteasome in yeast (9), while in human the tails of Rpt5 and Rpt3 seem to be important for 
assembly (10).  
 
The efficient assembly of the proteasome requires a number of chaperones. At least five 
chaperones assist in the assembly of the core particle (1,11). In addition to these, four chaperones 
have been identified that are important for the formation of the AAA-ATPase ring, known by 
their yeast/human names Hsm3/PSMD5 (a.k.a. S5B), Rpn14/PAAF1, Nas2/PSMD9 (a.k.a. p27), 
and Nas6/PSMD10 (a.k.a. gankyrin) (12-16). Each of these chaperones has been shown to bind 
to a specific AAA-ATPase present in the RP; Hsm3 binds to Rpt1, Nas2 to Rpt5, Rpn14 to Rpt6, 
and Nas6 to Rpt3. Although the chaperones lack sequence as well as structural homology 
amongst one another, they all bind to the same C-terminal region of their specific partner Rpt-
protein (14,16-18). Our understanding of how these chaperones assist in assembly at the 
molecular level is limited. As is typical for chaperones, these proteins are not present on the final 
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functional complex, assembled proteasomes. The chaperones have been suggested to directly 
facilitate assembly of neighboring ATPases, provide stability or bring sub-assemblies together 
(4,19). For Nas6, structural data and molecular modeling in combination with experimental data 
suggest that there is a steric hindrance preventing simultaneous binding of Nas6 and CP to Rpt3 
(9,14). Biochemical experiments suggest a similar property for Hsm3 and Rpn14 exists (9,14). 
Thus, one function of these chaperones might be to regulate the interactions of the Rpt proteins 
with the CP (20). For Nas2 this has not been studied in detail. Interestingly, Nas2 has a PDZ 
domain (15). Because PDZ domains often bind to the Cterminus of proteins, binding of Nas2 
might directly prevent docking of Rpt5 to the CP (15).  
 
Three other important regulators of proteasome in yeast that have been implicated in 
proteasome assembly are Ubp6, Ecm29 and Blm10. Each protein has a human orthologue; 
USP14, KIAA0368, and PSME4 (a.k.a.PA200) respectively. Ubp6 is a deubiquitinating enzyme 
that binds to the proteasome and regulates the degradation of ubiquitinated proteins (21).  
Interestingly it has been identified in an RP assembly subcomplex (9,16,22) and recent data 
suggest that it plays an active role in proteasome assembly (22). Blm10, like RP, binds to either 
end of the CP and has been found associated with CP or in a hybrid proteasome with CP and RP 
(23-25). Association of Blm10 with CP has been shown to increase suc-LLVY-AMC proteolytic 
activity and is required for the degradation of specific substrates (24,26,27). On the other hand it 
also has a function in assembly of the proteasome and has been observed in association with 
immature CP (28-30). Ecm29 is mainly found associated with RP-CP or RP2-CP complexes. It 
has been shown to stabilize proteasomes in the absence of ATP presumably by binding to the CP 
as well as the RP (31,32), suggesting it might have a positive role in proteasome function. 
However, recent publications describe Ecm29 as a chaperone or protein that monitors the quality 
of assembled proteasomes (33-35). One of these studies found Ecm29 associated with 
proteasomes that lack the β3 subunit and have stalled CP maturation (33). How Ecm29 
recognizes these proteasomes and how it regulates proteasomes remains unclear. 
 
In this study we show that Nas2 binds to the C-terminal tail of Rpt5, but does not require 
the last amino acid of Rpt5 that is essential for functional Rpt5-CP interaction. While binding of 
Nas2 to Rpt5 is likely to cause steric hindrance for the Rpt5-CP interactions, our phenotypic 
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analyses suggest that Nas2 functions beyond regulating this interaction. In rpt5-Δ3 cells, which 
are disrupted for the interaction between Rpt5 and CP as well as Rpt5 and Nas2, we see a strong 
increase in Ecm29-associated assembled proteasomes. These proteasomes seem to be 
compromised in their functionality as they have reduced suc-LLVYAMC hydrolytic activity. 
Consistent with a role for Ecm29 as a negative regulator, deletion of ECM29 rescues the 
phenotypes observed in nas2Δ or rpt5-Δ3 backgrounds. 
 
 Experimental Procedures 
Yeast strains  
See Supplementary Table 1 for genotypes of strains used. Standard methods for 
strain construction and cell culture were used. Plating assays were done as described before, 
using four-fold dilutions (14). 
Plasmids and antibodies  
For the expression of GST-Nas2 in E.coli we cloned the open reading frame of Nas2 into a 
pGEX-6P1 derived plasmid, creating plasmid pJR500. His-tagged full length Rpt5 or His-tagged 
Rpt5 C-domain (coding for amino acids 350 till 434) were cloned into the 
pRSFDuet-1 plasmid (Novagen) for expression in E.coli, creating plasmids pJR506 and pJR168 
respectively. To express the truncations of Rpt5 in E.coli plasmid pJR506 was mutated such that 
the last (pJR507) or last three codons (pJR508) before the stop codon were deleted. Similarly, 
plasmid pJR168 was used to construct deletions of the last 
(pJR509) or last three codons (pJR510) of the C-domain. For the detection of His tagged proteins 
we used THE® His tag monoclonal antibody (Genscript). Ecm29 was detected using an Ecm29 
polyclonal antibody, kindly provided by Dr. Dan Finley (Harvard Medical School, Boston MA). 
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Table 2.1 Yeast Strains 
Strain Genotypea (lys2-801 leu2-3, 2-112 ura3-52 his3-200 trp1-1) Figure Source 
    
SUB61 MAT  2.2,2.3,2.4a,2.6 (1) 
sDL133 MATa rpn11::RPN11-TEVProA (HIS3) 2.4b,c,2.5 (2) 
sMK60 MATα ecm29::TRP rpn11::RPN11-TEVProA (HIS3)  2.5 (3) 
sJR233 MAT hsm3::KAN nas6::TRP  2.6 (4) 
sJR236 MAT hsm3::KAN rpn14::HYG  2.6 (4) 
sJR239 nas6::TRP rpn14::HYG 2.6 (4) 
sJR245 hsm3::KAN 2.6 (4) 
sJR299 hsm3::KAN nas6::TRP ecm29::TRP 2.6 (5) 
sJR301 nas6::TRP rpn14::HYG ecm29::TRP 2.6 (5) 
sJR303 hsm3::KAN rpn14::HYGRO ecm29::TRP 2.6 (5) 
sJR515 MATA hsm3::KAN 2.3 (5) 
sJR518 MAT nas2::NAT, hsm3::KAN rpt5::rpt5Δ1-HYG 2.3 (5) 
sJR519 MATA nas2::NAT, hsm3::KAN rpt5::rpt5Δ3-HYG 2.3 (5) 
sJR528 MATA hsm3::KAN rpt5::rpt5Δ1-HYG 2.3 (5) 
sJR530 MATA hsm3::KAN rpt5::rpt5Δ3-HYG 2.3 (5) 
sJR534 nas2::NAT 2.2,2.3,2.4a (5) 
sJR535 rpt5:: rpt5Δ1-HYG 2.2,2.3,2.4a (5) 
sJR536 rpt5:: rpt5Δ3-HYG 2.2,2.3,2.4a (5) 
sJR539 nas2::NAT, rpt5::rpt5Δ1-HYG 2.3 (5) 
sJR540 nas2::NAT, rpt5::rpt5Δ3-HYG 2.3 (5) 
sJR544 MAT ecm29::TRP rpt5::rpt5∆3-HYG 2.6 (5) 
sJR545 MATa hsm3::KAN ecm29::TRP rpt5::rpt5∆0-HYG 2.6 (5) 
sJR546 MATA hsm3::KAN ecm29::TRP rpt5::rpt5∆3-HYG 2.6 (5) 
sJR548 ecm29::TRP rpt5::rpt5Δ3-HYG rpn11::RPN11-TEVProA (HIS3) 2.4b,c (5) 
sJR550 MATa hsm3::KAN ecm29::TRP rpt5::rpt5Δ3-HYG rpn11::RPN11-TEVProA (HIS3) 2.4b,c (5) 
sJR552 rpt5::rpt5Δ3-HYG rpn11::RPN11-TEVProA (HIS3) 2.4b,c (5) 
sJR554 hsm3::KAN rpt5::rpt5Δ3-HYG rpn11::RPN11-TEVProA (HIS3) 2.4b,c (5) 
sJR555 rpt5::rpt5Δ0-HYG 2.6 (5) 
sJR556 rpt5::rpt5Δ3-HYG 2.6 (5) 
sJR557 hsm3::KAN rpt5::rpt5Δ0-HYG 2.6 (5) 
sJR558 hsm3::KAN rpt5::rpt5Δ3-HYG 2.6 (5) 
sJR559 MAT ecm29::TRP 2.6 (5) 
sJR578 nas2::NAT hsm3::KAN ecm29::TRP  2.6 (5) 
sJR579 nas2::NAT hsm3::KAN  2.6 (5) 
a. All strains, except sJR387 and 388, have the DF5 background genotype6 ( lys2-801 leu2-3, 2-112 ura3-52 his3-200 
trp1-1 
1. Finley, D., Ozkaynak, E., and Varshavsky, A. (1987) Cell 48, 1035-1046 
2. Leggett, D. S., Hanna, J., Borodovsky, A., Crosas, B., Schmidt, M., Baker, R. T., Walz, T., Ploegh, H., and 
Finley, D. (2002) Mol Cell 10, 495-507 
3. Kleijnen, M. F., Roelofs, J., Park, S., Hathaway, N. A., Glickman, M., King, R. W., and Finley, D. (2007) 
Nat Struct Mol Biol 14, 1180-1188 
4. Roelofs, J., Park, S., Haas, W., Tian, G., McAllister, F. E., Huo, Y., Lee, B. H., Zhang, F., Shi, Y., Gygi, S. 
P., and Finley, D. (2009) Nature 459, 861-865 
5. This study 
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Proteasome purifications and native gels  
The affinity-purification of Rpn11-TeV-Protein A tagged proteasomes was performed as 
described before with minor modifications (36). Briefly, between 1 and 6 liter of overnight 
cultures (OD600 ~ 10) were spun down, washed in H2O, and a two-fold pellet volume of lysis 
buffer (50 mM Tris-HCl [pH 8], 1 mM EDTA, 5 mM MgCl2, 1 mM ATP) was added. Cells 
were lysed by French Press, and lysates were centrifuged at 12,000 rpm (SS34, Sorvall) at 4°C 
for 25 min. The supernatant was filtered through a cheesecloth, IgG beads (MP Biomedicals) 
were added (~0.5 ml / l culture), and the lysate was rotated at 4°C for one hour. The IgG beads 
were collected in an Econo Column (Biorad), and washed with ice-cold wash buffer (50 column 
volumes; 50 mM Tris- HCl [pH 7.5], 1 mM EDTA, 100 mM NaCl, 5 mM MgCl2, 1 mM ATP). 
Next, beads were washed with 15 column volumes of cleavage buffer (50 mM Tris-HCl [pH 
7.5], 1 mM EDTA, 1 mM DTT, 5 mM MgCl2, 1 mM ATP). Followed by cleavage in the same 
buffer containing His-tagged TeV protease (Invitrogen), for 1 hour at 30°C. Talon beads were 
added for 20 minutes at 4°C to remove TeV protease, after which the preparation was 
concentrated in a 10 kDa concentrator (Millipore). Proteasome preparations were stored at –
80°C. Proteasome preparations were analyzed using standard SDS-PAGE or on native gels 
prepared as described previously and run between 2 and 3 hours at 4ºC (37). Total lysates for 
analysis on native gel were prepared as described previously 
(14). 
 Apyrase treatment  
The apyrase treatment of purified proteasomes was performed as described previously with 
minor modifications (31). Purified proteasomes were diluted in 50mM Tris-HCl (pH 7.5), 5mM 
MgCl2, 1mM EDTA, and 0.25mM ATP. Samples were incubated for 45 min at 30°C with or 
without apyrase (20 mU μl-1 working concentration). After treatment proteasomes were 
analyzed using native gels. 
 Mass spectrometry 
CBB stained gel pieces were excised from native gel and proteins were digested with trypsin, 
followed by a peptide extraction and Nano-HPLC and Electrospray Ionization Tandem Mass 
Spectrometry (ESI−MS/MS). Peptide masses were compared to Swiss Prot Database using 
MASCOT 2.2 (http://www.matrixscience.com). For more details see supplementary table 2. 
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GST pull down  
GST-Nas2 and His-Rpt5, His- Rpt5-Δ1, or His-Rpt5-Δ3 were overexpressed in E. coli at 30°C 
for 3 hours. Cells were harvested and resuspended in lysis buffer (20mM Tris-HCl [pH8.0], 
100mM NaCl, 1mM EDTA, 1% Triton X-100, and protease inhibitors). Lysates were prepared 
by French Press and cleared by centrifugation. Lysates of GST-Nas2 and his-tagged proteins 
were mixed and incubated at 4°C for 1.5 hours. Glutathione sepharose beads were added to the 
mix and incubated at 4°C for 30 minutes to bind GST-Nas2. Beads were collected by 
centrifugation and washed 3x with lysis buffer. Samples were separated on SDS-PAGE for 
analysis. For His-Rpt5 C domain series, GSTNas2 and his-tagged proteins were co-expressed in 
E. coli and purified as above. 
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 Results 
In vitro Nas2-Rpt5 binding  
The proteasome contains six ATPases (the Rpt proteins) that belong to the AAA-ATPase 
family. AAAATPases typically have a C-domain (a.k.a. C-terminal domain) following the 
ATPase domain (38). Because the C-domain is in the C-terminal region of the Rpt proteins, it is 
generally considered to end at the C-terminus (14,16). However, crystal structure analysis of part 
of the archeal homolog of the proteasomal ATPases, the Proteasome-Activating Nucleotidase 
(PAN), show that the last twelve amino acids from the C-terminus are not structured (39). This 
suggests that these amino acids, referred to as the C-terminal tail or tail, are highly flexible and 
formally are not part of the preceding C-domain of PAN. A flexible tail is in agreement with the 
model that the tails of the Rpt proteins extend and partially dock into pockets located on the CP 
(5-7,40). The three C-terminal amino acids are tightly packed into the pockets upon docking 
(7,40). Thus, if binding of a chaperone requires these amino acids, it would suggest this 
chaperone directly interferes with docking of the Rpt tail into the CP pocket. For three of the four 
chaperones that bind to the C-domains of their respective Rpt protein, namely Nas6, Hsm3 and 
Rpn14, the last three amino acids are not required for binding to the C-domain (14). For the 
fourth chaperone, Nas2, two–hybrid studies have shown an interaction with the C-domain of 
Rpt5 (16). However it is unclear if this interaction requires any of the amino acids at the C-
terminal tail (20). Interestingly, Nas2 consists largely of a PDZ domain (15,16) and a subset of 
PDZ domains has been shown to bind specifically to the C-terminus of their binding partners 
(41,42). Consistent with this, the tail of Rpt5 shows a consensus motif II sequence for PDZ 
binding (Fig. 2.1A and B). Moreover, docking of the C-terminus of Rpt5 into a pocket present on 
the CP surface results in opening of the CP gate (5,6). Therefore, mapping the precise binding of 
Nas2 on Rpt5 potentially provides important insights into the molecular mechanisms of assembly 
and proteasome function. 
We set up an in vitro binding assay to analyze the interaction between Rpt5 and Nas2. 
Lysates expressing indicated proteins (Fig 2.1C, right panel) were mixed and incubated with 
glutathione resin. His-tagged Rpt5 specifically co-purified with GST-tagged Nas2, but not GST, 
(Fig. 2.1C, left panel, lane 1 and 4). To test if indeed the C-domain, including the tail, of Rpt5 
binds to Nas2 we co-expressed GST-Nas2 or GST with His-tagged Rpt5 C-domain, followed by 
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a purification using glutathione-resin (Fig. 2.1D, left panel, lane 1 and 2). These data show that 
the C-domain of Rpt5, in agreement with previous 2-hybrid data (16), is sufficient for binding to 
Nas2. Our in vitro data also show that this is a direct interaction between Nas2 and Rpt5. 
 
Next, we tested the requirement of the amino acids at the C-terminus of Rpt5 for Nas2 
binding. Deleting the last amino acid (Ala, Δ1) or the last three amino acids (Phe-Tyr-Ala; Δ3) 
did not change the expression level or solubility of His-tagged Rpt5 or His-tagged Rpt5 C-
domain in E.coli (Fig. 2.1 C and D, right panels). Nonetheless, hardly any Rpt5-Δ3 co-purified 
with GST-Nas2, while Rpt5-Δ1 and Rpt5 readily co-purified with GST-Nas2 (Fig. 2.1C and D, 
left panels). These results indicate that Nas2 depends on the C-terminal tail of Rpt5 for binding, 
but not on the C-terminal amino acid. 
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Figure 2.1 Nas2 binds to the tail of Rpt5 independent of the C-terminus. 
A, a subset of PDZ-domain containing proteins has been shown to bind to the C-termini of their 
binding partner. Three classes of C-termini binding PDZ domains have been identified based on 
the motif they bind to. Shown is the consensus motif as reported by (41,42) with X for any amino 
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acid and  indicating a hydrophobic amino acid. B, Last twenty amino acids of the S.cerevisiae 
proteasomal AAA-ATPases, Rpt1-6. Bold and underlined is shows the putative class II 
recognition sequence found in Rpt5. C, E.coli lysates expressing His-tagged Rpt5, Rpt5-1 or 
Rpt5-3 (right panel) were mixed with lysates expressing GST or GST-tagged Nas2. 
Glutathione-Sepharose-purified samples were separated on SDS-PAGE followed by Coomassie 
blue staining (left panel). D, His-tagged C-domains of Rpt5, Rpt5-1 or Rpt5-3 were co-
expressed with GST or GST-tagged Nas2 in E.coli (right panel). Glutathione-Sepharose-purified 
samples were separated on SDS-PAGE followed by either Coomassie blue staining ((left panel; 
top) or immunoblotting using a His-tag antibody (left panel; bottom). Comparable results were 
obtained with more than three independent purifications.  
 
 
The binding of Nas2 to Rpt5-Δ1 is surprising, because the deletion of the C-terminal 
amino acid of the Rpt5 eliminates the class II binding motif at the C-terminus of Rpt5 (Figure 
2.1A and B). However, this result is consistent with the absence of several amino acids, referred 
to as GLGF motif, in Nas2 (data not shown). The GLGF motif is normally conserved in C-
terminus binding PDZ domains and involved in the binding of the C-terminus (42). Thus, 
although Nas2 binds very close to the C-terminus, it does not belong to the PDZ domains that 
bind C-termini. 
Reduced 26S activity in Rpt5 mutants  
The tail of Rpt5 seems to provide two important functions. First, it is involved in the 
binding of Nas2, suggesting it has an important role in the assembly of the proteasome. Second, 
part of the tail docks into a pocket present in the proteasome CP. The docking of the Rpt5 tail 
opens the CP gate as well as stabilizes the CP-RP interaction (5,6). When we compared total 
lysates on native gel of wildtype, rpt5-Δ1 and rpt5-Δ3 strains, we observed an increase in free 
CP in the rpt5-Δ1 and rpt5-Δ3 strains together with a decrease in the level of singly and doubly 
capped proteasomes (Fig. 2.2). 
 
These observations can be explained by the compromised CP-RP interaction in the rpt5-
Δ1 and the rpt5-Δ3 strains. Because we observed in vitro that the rpt5-Δ3 protein interacts poorly 
with Nas2 (Fig. 2.1), the more severe reduction in 26S activity as observed for the rpt5-Δ3 strain 
(Fig. 2.2 top panel, lane 4 versus 5) can most likely be contributed to the combined effect of a 
docking defect and an assembly defect. The later caused by the disruption of the interaction 
between Rpt5 and Nas2. Alternatively, the rpt5-Δ3 strain might show a more complete 
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impairment of the interaction with CP. However, both the rpt5-Δ1 mutation and the rpt5-Δ3 
mutation are lethal in the rpn4Δ background as determined by tetrad analysis (data not shown), 
indicating that both the rpt5-Δ1 and the rpt5-Δ3 strains are severely compromised in an 
important role that the Rpt5 C-terminus performs in proteasome function. Rpn4 is a transcription 
factor for proteasome genes and at the same time is degraded by the proteasome, thereby 
providing an important feedback mechanism that is activated when proteasome function is 
compromised (43). In sum, both the rpt5-Δ1 and rpt5-Δ3 strains show phenotypes consistent 
with a defect in docking of Rpt5 onto the CP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Reduced LLVY-AMC hydrolytic activity for proteasome complexes of Rpt5 
mutants on antive gel.  
A, Cell lysates of wildtype, nas2 rpt5-1 or rpt5-3 were resolved on native gel (100 g 
protein/lane). Gels were stained for hydrolytic activity using the fluorogenic substrate LLVY-
AMC in the absence (top) or presence (bottom) of 0.02% SDS. The presence of SDS results in 
visualization of free CP, by opening the CP gate. The different CP containing complexes that can 
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be identified are indicated. The results shown are a representative example of more than three 
independent experiments. 
 
 Phenotypic analysis 
How Nas2 and the other chaperones function at the molecular level in assembly is not 
well understood. One model, supported by some experimental data, is that binding of Nas6, 
Rpn14 and Hsm3 to the C-domain of their respective Rpt protein antagonizes docking of the Rpt 
tail onto the CP (9,14). Structural studies show that the hydrophobic amino acids of the Hb-Y-X 
motif present in the tail of a number of Rpt proteins fits snugly into the CP pocket (7,40), 
indicating that the binding of Nas2 to Rpt5 would prevent Rpt5 from docking onto CP. If Nas2 
would function solely as a factor to prevent Rpt5-CP interaction one would predict that this 
function would become irrelevant when Rpt5 and CP do not interact, such as in the rpt5-Δ1. 
Thus if a deletion of NAS2 in an rpt5-Δ1 strain would cause a more severe phenotype, it would 
suggest that Nas2 might perform roles in assembly beyond regulating the Rpt5-CP interaction. 
To test this we performed some phenotypic analysis. Using strains deleted for NAS2 or 
containing the rpt5-Δ1 or rpt5-Δ3 mutation we did not observe any sensitivity for high 
temperature (Fig. 2.3). When we tested our mutants in the hsm3Δ background, the rpt5-Δ1 strain 
did not show any sensitivity at 37ºC (Fig. 2.3). However, upon deletion of NAS2 in this 
background, these cells became temperature sensitive. This suggests that Nas2 has additional, as 
of yet unidentified, functions during proteasome assembly. The nas2Δ hsm3Δ strain (15,16) and 
the hsm3Δ rpt5-Δ3 strain showed temperature sensitivity as well, since both grew poorly at 37ºC 
as well (Fig. 2.3). This is consistent with the notion that disruption of the Rtp5-Nas2 interaction 
in an HSM3 deletion background causes temperature sensitivity. The hsm3Δ rpt5-Δ3 strain 
appears to be somewhat more sensitive compared with nas2Δ hsm3Δ. Τhis can most likely be 
explained by the disrupted Rpt5-CP interaction in hsm3Δ rpt5-Δ3 strain. 
As mentioned before, the disruption of the Rpt5-CP interaction, as observed in the rpt5-
Δ3 or rpt5-Δ1 appears to be synthetic lethal with a deletion of RPN4. The deletion of NAS2 in an 
rpn4Δ strain is not lethal and nas2Δ rpn4Δ cells do not show temperature sensitivity either (data 
not shown). This is similar to what has been observed for deletions of the other individual 
chaperones in combination with RPN4 (14). In sum, strains in which the Nas2-Rpt5 interaction is 
33 
disrupted in the hsm3Δ background become sensitive for heat stress. Strains with compromised 
Rpt5 docking on the other hand display lethality in the rpn4Δ background. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Growth phenotype of nas2∆ correlates with rpt5-∆3 mutation in the hsm3∆ 
background. 
Strains with the indicated mutations or genes deleted were spotted on YPD plates in four- fold 
serial dilutions and grown at the indicated temperature for 2-3 days. Dilution assays were 
performed three times with at least two independent clones, each time showing similar growth 
patterns. 
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 Enrichment in Ecm29 
The lysate of rpt5-Δ1 strain shows a modest enrichment in a species that migrates slightly 
slower then RP-CP, while there also is a species migrating slightly slower than RP2-CP (Fig. 
2.2). This effect is consistently more pronounced in rpt5-Δ3 lysates, suggesting both the failure 
to interact with the CP as well as the failure to bind Nas2 contribute to this effect (Fig. 2.2). 
These slower migrating species can generally be attributed to retarded migration due to the 
binding of Ecm29 or Blm10 (24,31). Ecm29 can bind to RP2-CP or RP-CP. Blm10 can only bind 
to RP-CP, because Blm10, like RP, interacts with the ends of CP, and the binding to the same 
end of the CP is mutually exclusive between RP and Blm10 (44). 
 
To confirm that the slower migrating forms we observe are Ecm29 containing species, we 
used two approaches. First, we analyzed the presence of Ecm29 by performing immunoblots of 
the native gels (Fig. 2.4A). This experiment shows that the Ecm29 positive bands align with the 
retarded RP-CP and RP2-CP, indicating these bands contain Ecm29. Furthermore, comparing the 
signal of Ecm29 with Rpt5 in Figure 2.4A, suggests the ratio of Ecm29 containing proteasome is 
strongly increased in rpt5-Δ1 and especially in the rpt5-Δ3 strains. Second, we introduced a 
protein A tagged proteasome subunit (36) in the different strains and used this to affinity-purify 
proteasomes. SDS-PAGE analysis of these purified proteasomes showed an enrichment of a 
band at a molecular weight similar to Ecm29 in the rpt5-Δ1 and rpt5-Δ3 (Fig. 2.4B, lane 1 
versus 2, 4 and 6). This band was absent from ecm29 deletion strains (Fig. 2.4B, lanes 3,5 and 7). 
To confirm this was indeed Ecm29 we did an immunoblot using the same Ecm29 antibody that 
was used in Figure 2.4A (Fig. 2.4C). Next, the purified proteasomes were treated with apyrase to 
reveal the proteasomes that have Ecm29 associated with it. Apyrase converts ATP and ADP into 
AMP and thereby causes dissociation of the RP-CP interaction unless Ecm29 is present (31). 
Therefore, the reduction of RP2-CP or RP-CP levels and the concurrent increase in the level of 
free CP is an indication of the amount of proteasomes that did not have Ecm29 associated with it, 
while resistance to apyrase treatment reflect complexes that are associated with Ecm29. Wild-
type proteasomes have little Ecm29 associated, as most of the RP2-CP and RP-CP species 
disappear upon apyrase treatment and free CP dramatically increases (Fig. 2.4D lanes 1, 2, 11 
and 12).  
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Figure 2.4 rpt5-  
A, Cell lysates of wildtype, nas2 Rpt5-1 or Rpt5-3 were resolved on native gel (60 g 
protein/lane) and stained for hydrolytic activity in the presence of 0.02% SDS using the 
fluorogenic substrate LLVY-AMC  (right panel). Gels were also transferred to a membrane and 
probed with antibodies to Ecm29 or Rpt5. Two independent experiments showed similar results. 
B, Proteasomes were affinity-purified from strains with protein A-tagged Rpn11 in the presence 
of ATP. Samples were analyzed using SDS-PAGE and stained with CBB. C, Identical to B, only 
instead of CBB staining gels were transferred to a membrane and probed with an antibody to 
Ecm29. D, Proteasome preparations shown in (B) were incubated in the presence or absence of 
apyrase. Samples were subjected to native gel electrophoresis in the presence of ATP, and 
stained for LLVY-AMC hydrolytic activity in the presence or absence of 0.02% SDS. Third panel 
shows native gel stained with coomassie blue. Results shown in B-D are representative examples 
of at least three experiments using two independently purified proteasome preparations. 
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Proteasomes purified from rpt5-Δ1, rpt5-Δ3 and hsm3Δ rpt5-Δ3 strains show hardly an 
increase in free CP upon treatment with apyrase and almost all RP-CP species remain stably 
associated (Fig. 2.4 D, lanes 3, 4, 7,8, 13 and 14). This shows that these proteasomes are highly 
enriched in Ecm29, with almost every RP-CP species containing at least one Ecm29 molecule. 
This is consistent with what we saw for the lysates on native gel (Fig. 2.4A). To show that the 
observed stability upon apyrase treatment is indeed caused by Ecm29, we deleted ECM29 in the 
rpt5-Δ1, rpt5-Δ3 and hsm3Δ rpt5-Δ3 strains. Upon treatment of proteasome from ecm29Δ strains 
with apyrase, the levels of RP2-CP and RP-CP were strongly reduced, similarly to wildtype, with 
a concurrent increase in free CP (Fig. 2.4D; lanes 5,6,9,10, 15 and 16). Thus the rpt5-Δ1 and 
rpt5-Δ3 mutations cause a strong increase in proteasomes associated with Ecm29 and the 
majority of assembled proteasomes contain Ecm29. 
 
Ecm29 induced closing of the gate 
We observed a surprising SDS-induced increase in RP-CP and RP2-CP suc-LLVY-AMC 
hydrolytic activity on native gels in the rpt5-Δ3 strain (Fig. 2.2 and Fig. 2.4D lane 7 and 8; 
compare top and middle panel) as well as the rpt5-Δ1 and wildtype strain after apyrase treatment 
(Fig. 2.4D). SDS induces a strong increase in free CP activity, because SDS causes an artificial 
opening of the gate of the CP (45). However, the association of RP with CP also results in gate 
opening. Thus RP2-CP species normally do not display an increase of LLVY-AMC hydrolytic 
activity in the presence of SDS compared to the absence of SDS, while RP-CP might show an 
intermediate activation. The SDS stimulated activity seems to be exclusive for the proteasome 
species with retarded migration and more pronounced in the rpt5-Δ3 strain (Fig. 2.4D) 
suggesting this effect depends on the presence of Ecm29. Alternatively, it could be specific for 
the rpt5-Δ3 strain, as Rpt5 reportedly plays a role in gate opening (5,6). We favor the earlier, 
because the SDS stimulation was not observed for protesomes purified from a rpt5-Δ3 ecm29Δ 
strain (Fig. 2.4D) and a similar effect has been observed in other mutants strains as well (Park et 
al. JBC in press). Furthermore, hsm3Δ and nas2Δ strains show the same SDS activation for the 
Ecm29-RP-CP species (Fig. 2.2 and data not shown). Thus the activation by SDS seems specific 
for RP-CP complexes that have Ecm29 associated. To test if the association of Ecm29 might 
37 
affect SDS dependent stimulation of LLVY-AMC activity in strains without any other mutations, 
we compared wildtype proteasomes with and without Ecm29. 
 
 
 
Figure 2.5 Ecm29-containing proteasomes have reduced activity in the absence of SDS. 
Proteasomes were affinity-purified from cell lysates of wildtype in the absence of ATP, which 
results in the purification of Ecm29 containing RP-CP and RP2-CP, or from ecm29 cells in the 
presence of ATP. As a control CP was affinity purified as well, using a strain with protein A 
tagged pre1 strain.  Samples were subjected to native gel in the presence of ATP and stained for 
suc-LLVY-AMC hydrolytic activity in the presence or absence of SDS. Results shown represent 
one of two independent experiments that yielded similar results. 
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To do this, we purified proteasomes from an ecm29Δ strain in the presence of ATP or 
from wildtype cells in the absence of nucleotide. In the absence of nucleotide all the 26S 
proteasomes purified from the wildtype strain contain Ecm29 (31). Native gel analysis of these 
purified proteasome show that RP-CP species containing Ecm29 are strongly activated by SDS 
as is CP, while RP-CP species lacking Ecm29 are not (Fig. 2.5). Because the only known role of 
SDS is opening the gate, these data strongly suggest that Ecm29 containing proteasomes have 
the gate in a closed conformation. Proteasomes containing Ecm29 might therefore be less active 
and have reduced functionality, a property consistent with the recently proposed quality control 
function of Ecm29 (33). 
 
Ecm29 proteasomes contain all subunits 
In a paper proposing the quality control function of Ecm29, Lehman et al. suggest that 
the observed reduction of the relative hydrolytic activity for Ecm29-bound RP-CP species is 
caused by incomplete CP maturation (33). However, the observed hydrolytic activity of the 
Ecm29 containing proteins in our native gel assays, especially in the presence of SDS, suggest 
that these proteasomes have mature active sites. In addition to incompletely maturation of CP, 
Lehman et al. argue that all Ecm29 containing proteasomes lack the CP subunit β3 (33). To test 
if the Ecm29 containing proteasomes in our system lack β3 we purified proteasomes from a 
wildtype strain as well as an rpt5-Δ3 strain. Even though almost all 26S purified from the rpt5-
Δ3 strain is associated with Ecm29 (see Fig. 2.4D), we treated rpt5-Δ3 strain derived 
proteasomes with apyrase to dissociate any RP-CP complexes that do not contain Ecm29. Next, 
samples were loaded on a native gel to separate RP2-CP complexes from other proteasome 
complexes and analyzed the proteasome subunit composition of the Ecm29 containing RP2-CP 
using mass spectrometry. Analysis of two independent purifications show the presence of all 
core particle subunits, including β3, in Ecm29 containing RP2-CP proteasomes purified from 
rpt5Δ3 strain (Fig. 2.6). Thus, under our conditions the presence of Ecm29 does not correlate 
with the absence of β3. 
  
39 
 
Figure 2.6 LC-MS/MS Analysis of Ecm29-Bound RP2-CP 
To determine the presence of the CP subunit β3 in Ecm29-RP2-CP proteasomes complexes 
derived from the rpt5-Δ3 strain, purified proteasomes samples were treated with apyrase and 
separated on a native gel. As a positive control wildtype proteasomes without apyrase treatment 
were loaded on gel. The band containing doubly capped proteasomes was excised from each 
lane and submitted for analysis by mass spectrometry. Mass spectormetry of samples from two 
independent purifications for both wildtype and Rpt3-Δ3 proteasomes proteasome showed very 
similar results. All proteasome subunits, with the exception of sem1, were identified in all fours 
sample. Sem1 was only detected in the second purification of wildtype and mutant proteasomes 
(data not shown). The initial absence can probably be explained by the small size of Sem1 which 
can hinder its detection, even if present. For Mass spectrometry analysis CBB stained gel pieces 
were destained using 50% acetonitrile (ACN) at 30 °C. After destaining, the gel pieces were 
shrunk by addition of 50 μl of 100% ACN for 10 min and solvent was discarded. The gel pieces 
were dried by speed vacuum concentrator. To rehydrate the gel in 20 μL 20 mM ammonium 
bicarbonate supplemented with 200 ng sequencing grade trypsin (Trypsin Gold, Promega, 
Madison, WI), was added. Next, 20 μL of 20 mM ammonium bicarbonate and 10% ACN was 
added, and gel pieces were incubated at 30°C for 17 h. Tryptic peptides were recovered from gel 
plugs by extraction with 100 μL of 50% ACN in 2% trifluoroacetic acid (TFA) at 30 °C for 30 
min. 
Extracted peptides were concentrated by speed vacuum concentrator and added to 100 μL of 2% 
ACN in 0.1% formic acid. 30 μL Peptide solution was loaded on a C18 reversedphase capillary 
column (75 μm ID Å~ 15 cm, PepMap: Dionex) in conjunction with an Acclaim C18 PepMap 
trapping column (300 μm idÅ~10 mm, Dionex) using Nano-HPLC was performed automatically 
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using a microcolumn switching device (Switchos; LC Packings) coupled to an autosampler 
(Famos: LC Packings) and a nanogradient generator (UltiMate Nano HPLC; LC Packings). . 
Peptides were separated by a nanoflow linear ACN gradient using buffer A (0.1% formic acid, 
2% ACN ) and buffer B (0.1% formic acid, 80% ACN) starting from 5% buffer B to 70% over 55 
min at a flow rate of 200 nL/min. Then column was washed by 95% of buffer B for 5 min. The 
system control software, Hystar 3.2, was used to control the entire process. The eluted peptides 
were injected into an HCT Ultra Ion Trap Mass Spectrometer (Bruker Daltronics). The mass 
spectrometer was set up in the data dependent MS/MS mode to alternatively acquire full scans 
(m/z acquisition range from 300 to 1500 Da). The four most intense peaks in any full scan were 
selected as precursor ions and fragmented by collision energy. MS/MS spectra were interpreted 
and peak lists were generated by DataAnalysis 3.4 and Biotools 3.0 software (Bruker 
Daltronics). 
Peptide masses were compared to Swiss Prot Database using MASCOT 2.2 
(http://www.matrixscience.com). Saccharomyces Cerevisiae was selected for the taxonomy. The 
following parameters were used in all searches: the maximum number of missed cleavages 
allowed was 2; the mass tolerance was 1.2 Da for MS and 0.6 Da for MS/MS. Fixed modification 
was set on cystein with carbamidomethylation. Variable modification was done on methionine 
with oxidation. Positive protein identifications using a threshold of 0.05 were used. Peptides 
scoring <20 were automatically rejected, ensuring all protein identifications were based on the 
reliable peptide identifications. 
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 Rescue by ECM29 deletion  
The increased association of Ecm29 to rpt5-Δ3 derived proteasomes might fulfill one of 
two different functions based on the reported roles of Ecm29. First, Ecm29 binding might 
stabilize the RP-CP interaction for these compromised proteasomes. If Ecm29 would provide 
only stabilizing functions, its absence would attenuate proteasome function and presumably 
cause more severe phenotypes. On the other hand if Ecm29 would act as a negative regulator that 
inhibits faulty proteasomes, its absence might be beneficial for cells with large amounts of faulty 
proteasomes. We tested the effect of deleting ECM29 on the phenotype to assess if it rescues or 
exacerbates the phenotypes of hsm3Δ rpt5-Δ3 strain. The deletion of ECM29 in the hsm3Δ rpt5-
Δ3 strains showed a rescue of the temperature sensitivity, suggesting Ecm29 actually functions 
as a negative regulator of proteasome assembly or function (Fig. 2.7 upper panel). If the 
observed effects of Ecm29 are in part related to the failure of Rpt5 binding to Nas2, the nas2Δ 
hsm3Δ cells should also be rescued by a deletion of ECM29. The deletion of ECM29 indeed 
rescues the nas2Δ hsm3Δ temperature sensitivity, although the rescue is not as robust as for the 
hsm3Δ rpt5-Δ3 strain (Fig. 2.7 middle panel). To confirm that these phenotypic rescues are not 
the result of a rescue of hsm3Δ, we tested if the hsm3Δ rpn14Δ or the hsm3Δ nas6Δ are rescued 
by a deletion of ECM29. Both strains are not rescued by the deletion of ECM29 (Fig. 2.7 lower 
panel), while they are rescued by overexpression of Rpt1 (14). Overexpression of Rpt1 is known 
to compensate for the absence of Hsm3 (14). Furthermore, the nas6Δ rpn14Δ strain is also not 
rescued by a deletion of ECM29, indicating that only deletions of NAS2, but not other RP 
chaperone genes, is rescued by a deletion of ECM29. 
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Figure 2.7 rpt5-∆3 and nas2∆ in the hsm3∆ background can be rescued by the deletion of 
Ecm29. 
Strains with the indicated mutations or genes deleted were spotted on YPD plates in four-fold 
serial dilutions and grown at the indicated temperature for 2-3 days. Dilution assays were 
performed three times with at least two independent clones, each time showing similar growth 
patterns. 
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 Discussion 
The identification of four chaperones that assist in the assembly of the proteasome 
regulatory particle provides a remarkable example of convergent evolution (9,13-16), since these 
chaperones do not display any genetic or structural relatedness. Even more remarkable is that 
each of the four chaperones binds to the C-domain of a specific paralogous AAA-ATPase. The 
data presented here show that Nas2, unlike the other chaperones, requires the last three amino 
acids of the Rpt protein for its interaction with this protein. This suggests that Nas2 will interfere 
with the docking of the Rpt5 tail into the CP, because the C-terminal three amino acids of the tail 
of Rpt5 are tightly packed in a CP pocket upon docking (7,40). Thus Nas2, has the potential to 
regulate the interaction of the Rpt protein with the CP by a more direct mechanism as compared 
to Rpn14, Nas6 and maybe Hsm3 (9,14). Our data also suggests that when studying the rpt5-Δ3 
mutant in vivo (10), one is looking at the cumulative effect of the disruption of two interactions. 
Using different mutants we were able to dissect the importance of the different interactions: the 
rpt5-Δ1 strain, which is compromised in Rpt5-CP interaction; the nas2Δ strain, which lacks the 
Rpt5-Nas2 interaction; and the rpt5-Δ3 strain, which is compromised in both Rpt5-CP and Rpt5-
Nas2 interactions. 
 
If the only function of Nas2 would be to prevent docking of Rpt5 tail into a pocket 
located on the CP, Nas2 function would become irrelevant in the rpt5-Δ1 strain, where the Rpt5-
CP interaction is compromised. However, deletion of NAS2 in the hsm3Δ rpt5-Δ1 strain results 
in temperature sensitivity, indicating Nas2 has functions beyond preventing the docking of Rpt5 
into a CP pocket. We are currently investigating what other functions Nas2 has. Nas2 might e.g. 
facilitate the formation of specific intermediate assembly complexes or could prevent formation 
of off-pathway products. Alternatively Nas2 might stabilize Rpt5, as has been suggested for the 
human homolog p27 (12), although over-expression of Rpt5 in yeast does not rescue the 
temperature sensitivity of nas2Δ hsm3Δ strains (data not shown). 
 
We observed that the combined failure of the Nas2-Rpt5 and the Rpt5-CP interaction by 
means of the rpt5−Δ3 mutant causes a dramatic accumulation of Ecm29 on the RP-CP and RP2-
CP proteasome species. There have been several publications showing Ecm29 is a stabilizing 
factor for the RP-CP interaction in the absence of ATP (31,32). However, more recent 
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publications suggest it is also a negative regulator or quality control protein for proteasome 
assembly (33-35). These roles might appear contradictory, but our data actually suggest that both 
phenomena happen synchronously. We observed that Ecm29-containing proteasomes remain 
stable upon removal of ATP and display reduced suc-LLVY-AMC hydrolytic activity in the 
absence of SDS. In the presence of SDS suc-LLVY-AMC hydrolytic activity is restored. The 
mechanism for SDS activation is generally believed to involve an artificial opening of the CP 
gate by disrupting the interaction between the N-termini of the CP α subunits, which then 
facilitates substrate entry. Therefore our data suggest that upon binding with proteasomes Ecm29 
actually enforces a (partially) closed gate and thereby inhibits the proteasome. Thus, Ecm29 
could function as a quality control protein, if it would recognize and inhibit “faulty” 
proteasomes. 
 
Although we currently have no molecular insight into if and how Ecm29 recognizes 
defective proteasomes, there are data that suggest Ecm29 recognizes such proteasomes. First, we 
saw enrichment in Ecm29 containing proteasomes in our rpt5-Δ1 and rpt5-Δ3 backgrounds. 
Second, RP-CP complexes in which the β3 subunit is absent and the active sites of the CP not 
properly matured show association with Ecm29 (33). Finally, upon oxidative stress there is an 
increased association of Ecm29 with RP (34). While we favor a model with specific recruitment 
of Ecm29 to faulty proteasomes, increased cellular levels of Ecm29 might also directly 
contribute to the enrichment in Ecm29 on proteasomes (Park et al. JBC in press). 
 
Earlier work suggested that Ecm29 association with proteasomes coincides with the 
absence of the CP β3 subunit (33). The absence of β3 also causes the lack of matured active 
sites. Under our conditions it seems unlikely that CP maturation defects cause the recruitment of 
Ecm29, because the Ecm29 containing proteasomes show robust proteolytic activity in the 
presence of SDS. It is more plausible that failure in CP as well as RP assembly can result in the 
recruitment of Ecm29. Ecm29 could specifically recognize conformations in each path, or it 
might be able to recognize a specific signal at some integration point. The later seems possible 
considering the interaction between RP and CP regulates gate opening and the binding of Ecm29 
affects the gate. Interesting to note is the presence of an allosteric communication that occurs 
between the proteolytic active sites inside the CP and CP-RP interface (31,46). Thus, immature 
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active sites of the CP could affect the CP-RP interaction as well. Therefore, if Ecm29 would 
recognize some misalignment between CP and RP it would have the potential to be able to 
“sense” a variety of faulty proteasomes, even if the cause is from a different origin. Since Ecm29 
has been reported to bind to the CP as well as the RP (32), one can envision subtle changes 
affecting the relative position of the two binding sites might function as a sensor of improper RP-
CP alignment. 
 
Although our data indicates a function of Ecm29 in recognizing and inhibiting faulty 
proteasomes, it is unclear if Ecm29 always inhibits the proteasome, since Ecm29 also appears to 
function as an adaptor that anchors proteasomes to specific cellular compartments (47,48). 
Furthermore, while we have shown in vitro that Ecm29 stabilizes proteasomes in the absence of 
ATP or ADP, other recent publication suggests that Ecm29 might cause dissociation of RP-CP 
complexes under different conditions (33,34). Ecm29 induced dissociation might make sense as 
part of a mechanism to recognize and restore faulty proteasomes. 
 
Figure 2.8 explains our observations in respect to a model. In wildtype cells the majority 
of proteasomes are assembled correctly. Nas2 mediated assembly is normal and the Rpt5 tail can 
dock into the core particle. Thus, there is only a small population of proteasomes associated with 
Ecm29. It could be that during normal assembly there is a transient functional association with 
Ecm29, or there is always a low background of faulty proteasomes present. Upon deletion of the 
Rpt5 C-terminal amino acid (Fig. 2.8 second row) Rpt5 does not dock properly onto CP, but in 
the presence of Nas2 this does not cause a major defect in assembly. This results in an increase 
in association of Ecm29 with the proteasome, but there is a substantial pool of proteasomes that 
are not bound or recognized by Ecm29 and are fully active. This provides a medium level of 
activity that is sufficient to cope with stress conditions such as heat, especially when the cell is 
able to compensate for reduced proteasome function using the rpn4 based feedback mechanism. 
However, the combined mutation with rpn4Δ causes lethality, indicating the docking of the 
Rpt5-Δ1 protein into the CP pocket is severely compromised. In rpt5−Δ3 there is a defect in 
docking in combination with a defect in assembly since the interaction between Nas2 and Rpt5 is 
disrupted as well (Fig. 2.8 third row). This presumably causes an increase in faulty proteasomes.  
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Figure 2.8 Model explaining and summarizing the role of the Rpt5 tail in proteasome 
assembly. 
In wildtype cells Rpt5 (indicated with the blue triangle) contains a tail of about 12 amino acids 
that are predicted to be unstructured and not part of the preceding C-domain. The tail is 
depicted in orange with the last three amino acids shown as green blocks. This tail has two 
functions. First it interacts with the chaperone Nas2 (indicated with the red triangle). Second the 
tail contains a Hb-Y-X consensus motif and has been shown to dock into a pocket present on the 
CP. Both interactions are mutually exclusive. Without disruption of either function, proteasomes 
assemble normally and have little Ecm29 associated with them. These proteasomes display high 
hydrolytic activity towards the substrate suc-LLVY-AMC. B, Upon the deletion of the C-terminal 
amino acid of Rpt5, the functional binding to CP is disrupted, while the binding to Nas2 is still 
functional. Under these conditions there is a modest increase in the formation of faulty 
proteasomes (indicated by the misalignment of CP-RP) which have Ecm29 associated, but there 
is a substantial amount of proteasomes remaining that do not have Ecm29 associated with them. 
C, Deleting three amino acids from the C-terminal end of Rpt5, results in the loss of both Nas2 
binding and proper CP docking. Under these conditions almost all proteasomes formed have 
Ecm29 associated with them. Although it is unclear what signal recruits Ecm29 to these 
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proteasomes, we propose that Ecm29 functions as a quality control protein that recognizes 
proteasomes because of a misalignment between CP and RP. These Ecm29 associated 
proteasomes show a strongly reduced LLVY-AMC hydrolytic activity, suggesting the function of 
Ecm29 might be to recognize and inhibit faulty proteasomes. D, This model predicts that the 
deletion of Ecm29 would remove inhibition of the proteasome and actually rescue cells with a 
substantial amount of faulty proteasomes, by increasing their cellular proteolytic potential. 
 
 
These faulty proteasomes are then recognized by and bound to Ecm29 resulting in low 
proteasome activity. This prevents this strain from being able to cope with heat stress in e.g. the 
hsm3Δ background. Deleting ECM29 in this background, does not restore the defective 
proteasomes, but removes the inhibition of the defective proteasomes (Fig. 2.8 fourth row). Thus 
these cells have again a substantial amount of proteasome activity that enables them to deal with 
a certain amount of heat stress. 
 
In mutants where faulty proteasomes can be restored or make up a minor portion of the 
total proteasomes, it might be preferable to have Ecm29 inhibit these proteasomes. This will 
ensure the cell has a pool of proper proteasomes and no active faulty proteasomes. However, 
under conditions where large amounts of faulty proteasomes are formed, such as in our rpt5-Δ3 
mutant, Ecm29 would be inhibiting a large fraction of proteasomes. Therefore, a particular cell 
might be better off to have fully active, albeit faulty, proteasomes. This would explain how the 
deletion of ECM29 can rescue the phenotypes of specific strains. However, under conditions 
where the absence of Ecm29 would not restore proteolytic activity, e.g. because defects in core 
particle assembly caused the association of Ecm29, deleting ECM29 might actually exacerbate 
the phenotype. Such an exacerbated phenotype has e.g. been reported for ecm29Δ ump1Δ and 
ecm29Δ blm10Δ (24,33). 
 
From our data it is clear that both the Rpt5-CP and the Rpt5-Nas2 interaction are 
important for proper proteasome formation.  Interestingly, the compromised interaction of Rpt5 
with Nas2 does not simply cause a reduced or slower assembly of normal proteasomes, but 
causes the formation of proteasomes associated with Ecm29. Delineating the mechanism by 
which these proteasomes are recognized by Ecm29 will be important for understanding at the 
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molecular level how Rpt5 and Nas2 function in proteasome assembly as well as how Ecm29 
plays a role as a negative regulator and putative quality control protein. 
 
 
A.D.L.M., S.Y.L, and J.R. conceived the experiments, S.Y.L performed experiments in 
figures 1, 2 and 4a. A.D.L.M conducted all other experiments. A.D.L.M. , S.Y.L. and J.R. 
analyzed and interpreted the data. A.D.L.M., S.Y.L. and J.R. wrote the manuscript with input 
from all coauthors.  
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 Abstract 
Several proteasome-associated proteins regulate degradation by the 26S proteasome 
using the ubiquitin chains that mark most substrates for degradation. The proteasome-associated 
protein Ecm29, however, has no ubiquitin-binding or modifying activity and its direct effect on 
substrate degradation is unclear. Here, we show that Ecm29 acts as a proteasome inhibitor. 
Besides inhibiting the proteolytic cleavage of peptide substrates in vitro, it inhibits the 
degradation of ubiquitin-dependent and independent substrates in vivo. Binding of Ecm29 to the 
proteasome induces a closed conformation of the substrate entry channel of the core particle. 
Furthermore, Ecm29 inhibits proteasomal ATPase activity, suggesting the mechanism of 
inhibition and gate regulation by Ecm29 is through regulation of the proteasomal ATPases. 
Consistent with this, we identified through chemical crosslinking that Ecm29 binds to, or in close 
proximity to, the proteasomal ATPase subunit Rpt5. Additionally, we show that Ecm29 
preferentially associates with both mutant and nucleotide depleted proteasomes. We propose that 
the inhibitory ability of Ecm29 is important for its function as a proteasome quality control factor 
by ensuring that aberrant proteasomes recognized by Ecm29 are inactive.  
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 Introduction 
The proteasome is the major cytosolic protease in eukaryotes. The 26S proteasome 
holoenzyme consists of a core particle (CP) with one or two regulatory particles (RPs), giving 
rise to a protease complex of about 2.5 MDa in size.  Many proteasome substrates are marked for 
degradation by the covalent attachment of a polyubiquitin chain (1-3). The first step in 
degradation is the selection of substrates by a large number of E2 and E3 enzymes that mark 
specific proteins for degradation. However, additional steps of potential regulation are present at 
the proteasome. This includes substrate delivery to the proteasome, as well as recognition and 
deubiquitination by the proteasome. These are facilitated by proteasome-intrinsic ubiquitin 
receptors, like yeast Rpn10 (human PSMD4) and Rpn13 (ADRM1); shuttling factors, like Rad23 
(RAD23A/B); and proteasome-associated deubiquitinating enzymes, like Ubp6 (USP14) (1,4). 
Finally, substrates require unfolding by the proteasomal AAA-ATPase (the Rpt proteins) and 
translocation to the inside of the cylindrically shaped CP where proteolysis occurs.  
 
The ability to inhibit protein degradation by the proteasome using chemical inhibitors of 
the proteolytic sites has resulted in the development of the FDA-approved treatment of multiple 
myeloma using the proteasome inhibitor Bortezomib (5). In the cell, however, few protein-based 
proteasome inhibitors have been characterized. In humans, the reported proteasome inhibitors 
PI31/PSMF1 (6), Rpn14/PAAF1 (7) and S5b/PSMD5 (8) do not directly inhibit the 26S 
proteasome. PI31/PSMF1 binds to the CP, competes with RP for CP binding (6), and might have 
a role in regulating RP-CP association (9).  Both Rpn14 and Hsm3, the yeast orthologs of 
Rpn14/PAAF1 and S5b/PSMD5 respectively, bind to RP and compete with CP for RP binding 
(10-13). They also have an important role as proteasome specific chaperones (3,14). The 
proteasome is also regulated by posttranslational modifications, which most likely provide an 
extra level of tuning in its activity (e.g. (15,16)). The closest to a non-chemical inhibitor of the 
26S proteasome currently seems to be Ubp6 (USP14), a deubiquitinating enzyme that interacts 
with the proteasome (17). This protein delays the degradation of ubiquitinated substrates in part 
through a mechanism that does not require the deubiquitinating activity (18,19). Additionally, 
Ubp6 has been reported to stimulate gate opening in an ubiquitin-conjugate dependent fashion 
(20). Although the mechanisms of regulation are not well understood, Ubp6 appears to be 
specific for ubiquitinated substrates. One of the initial screens that identified Ubp6 as a 
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proteasome-associated protein in yeast also identified Ecm29 whose function has remained more 
elusive (17). Ecm29 and the human ortholog KIAA00368/ECM29 bind specifically to 26S 
proteasomes (17,21).  Ecm29 has been reported to stabilize proteasomes (17,22), remodel 
proteasomes upon stress (23,24), be involved in membrane-associated localization of 
proteasomes (21,25), and, more recently, be involved in quality control or assembly of the 
proteasome (23,26-28).  Despite these numerous associations, the molecular effects of Ecm29 
binding to the 26S proteasome remain poorly understood. 
 
In this study we show that Ecm29 preferentially binds to nucleotide-depleted as well as 
certain mutant proteasomes. Upon binding to proteasomes, Ecm29 inhibits the in vivo and in 
vitro degradation of substrates. Binding of Ecm29 to the proteasomes causes a closed gate 
conformation and, more importantly, causes an inhibition of proteasomal ATPase activity. The 
latter can explain the observed reduction in in vivo degradation in the presence of Ecm29. 
 
 Experimental Procedures 
 Yeast strains.  
See Table 1 for the genotypes of strains used. DNA fragments used to generate C-
terminal truncations of Rpt5 at the genomic locus were made by PCR using pYM24 (29) as 
template and oligos pRLs2-Rpt5 (AAT ATG TAG ATA TGT GAA TGG CGG CTT GAT AAA 
TCA AAA TAT TAT TAT TTA TCG ATG AAT TCG AGC TCG) and  pRL-s3Rpt5d0 (GTA 
TAA GTG AAG TTC AAG CAA GAA AAT CGA AAT CGG TAT CCT TTT ATG CAT AGG 
GCG CGC CAG ATC TGT T) for rpt5-0 (i.e. no truncation control),  oligos pRLs2-Rpt5 and  
pRL-s3Rpt5d1 (AGG GTA TAA GTG AAG TTC AAG CAA GAA AAT CGA AAT CGG TAT 
CCT TTT ATT AGG GCG CGC CAG ATC TGT T) for rpt5-1 (i.e. deletion of last amino 
acid), and oligos pRLs2-Rpt5 and  pRL-s3Rpt5d3 (TCG TTG AGG GTA TAA GTG AAG TTC 
AAG CAA GAA AAT CGA AAT CGG TAT CCT AGG GCG CGC CAG ATC TGT T) for 
rpt5-3 (i.e. deletion of last three amino acids). DNA fragments used to exchange the 
endogenous promoter of ECM29 at the genomic locus, were made by PCR using pYM-N15 (29) 
as template and oligos pRL194 (TCT CCA CGA GCT GTT TTT CTT TCG CTT CGT CAG 
56 
AAG AAA TGG ATC CGG AAT GGT GAT GGT GAT GGT GGT GCA TCG ATG AAT TCT 
CTG TCG) and pfEcm29NtagS1 (CAA TAA TTA TAG AAA AGT TTC TAT TTC ACC ACG 
AAC AAC ATT CGT ACG CTG CAG GTC GAC). Standard methods for strain construction 
and cell culture were used.  Plating assays were done as described before, using 4-fold dilutions 
(11).  
 Antibodies.  
Ecm29 was detected using an Ecm29 polyclonal antibody, kindly provided by Dr. Dan 
Finley (Harvard Medical School, Boston, MA).  Rpt4 and Rpt5 were detected using monoclonal 
anti-Rpt4 and anti-Rpt5, kindly provided by Dr. William Tansey (Vanderbilt-Ingram Cancer 
Center, Nashville, TN).   Monoclonal anti-FLAG (Sigma) was used for detection of Flag-ODC.  
Monoclonal anti-β-Galactosidase antibody (Promega) was used for detection of β-galactosidase. 
Polyclonal anti-Ubiquitin antibody (Enzo) and monoclonal anti-T7 (Novagen) were used for the 
detection of ubiquitinated substrates, and anti-Pgk1 antibody (Invitrogen) was used as a loading 
control. Peroxidase conjugated secondary antibodies were used (Jackson Imuno research lab).  
 Imaging.  
All images were acquired using a Gbox imaging system (Syngene) with GeneSnap 
software. To determine the relative levels of Ecm29 in figure 6, peak volumes for the different 
bands were determined using the Genetool analysis software from Syngene and values for each 
Ecm29 signal were corrected for input using the Rpt5 immunoblot. These corrected values were 
normalized to the signal for ATP without proteasome inhibitor (Fig. 8A) or ecm29Δ with ATP 
(Fig. 8C). Data shown are average from 2 to 4 independent experiments. 
 Proteasome purifications and native gels.  
The affinity purification of Pre1-TeV-protein A-tagged proteasomes was performed as 
described before with minor modifications  (17). Briefly, between 1 and 6 liters of overnight 
cultures (A600 = ~10) were collected, washed in H2O, and resuspended in two pellet volumes of 
lysis buffer (50 mM Tris-HCl [pH 8], 1 mM EDTA, 5 mM MgCl2, 1 mM ATP). The cells were 
lysed by French press and lysates were cleared by centrifugation (20,000 g, 4 °C for 25 min). 
The supernatant was filtered through a cheesecloth, IgG beads (MP Biomedicals) were added 
(~0.5 ml/liter of culture), and the lysate was rotated at 4 °C for 1 h. The IgG beads were collected 
57 
in an Econo Column (Bio-Rad) and washed with ice-cold wash buffer (50 column volumes; 50 
mM Tris-HCl [pH 7.5], 1 mM EDTA, 100 mM NaCl, 5 mM MgCl2, 1 mM ATP). Next, beads 
were washed with 15 column volumes of cleavage buffer (50 mM Tris-HCl [pH 7.5], 1 mM 
EDTA, 1 mM DTT, 5 mM MgCl2, 1 mM ATP), followed by cleavage in the same buffer 
containing His-tagged TeV protease (Invitrogen) for 1 h at 30 °C. Talon beads were added for 20 
min at 4 °C to remove TeV protease, after which the preparation was concentrated in a 10-kDa 
concentrator (Millipore).  Proteasome preparations were stored at -80 °C. For the purifications 
without nucleotide, no ATP was added to any of the solutions.  Proteasome preparations were 
analyzed using standard SDS-PAGE or on native gels prepared as described previously and run 
between 2 and 3 h at 4 °C (30). Total lysates for analysis on native gel were prepared as 
described previously (11). 
 Apyrase Treatment.   
The apyrase treatment of purified proteasomes was performed as described previously 
with minor modifications (22). Purified proteasomes were diluted in 50 mM Tris-HCl [pH 7.5], 5 
mM MgCl2, 1 mM EDTA, and 0.25 mM ATP. Samples were incubated for 45 min at 30°C with 
or without apyrase (20 milliunits μl-1 working concentration). After treatment, proteasomes were 
analyzed using native gels. 
 β-galactosidase assay.   
Cells were grown overnight in SD media without lysine and supplemented with 100 mM 
CuSO4. The cell equivalent to 5ml of OD600 1 was collected and cells were lysed in 200 μl 
breaking buffer (100 mM Tris-HCl [pH 8.0], 1 mM DTT, 20% glycerol, 1 mM PMSF) by 
vortexing in the presence of glass beads.  An additional 200 μl of breaking buffer was added and 
mixed.  After centrifugation at 16,000 g for 5 minutes, 100 μL of the cleared lysate was mixed 
with 900 μl of Z buffer (60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4, 50 
mM β-mercaptoethanol) and incubated for 5 min at 30°C.  After incubation, 200 μl of 4 mg/ml 
O-nitrophenyl-β-D-galactosidase (ONPG) was added to the mixture followed by an incubation at 
30°C for 30 min.  The reaction was terminated by the addition of 500μl of 1 M Na2CO3. 
Absorbance was read at 420 nm. 
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Sic1PY degradation assay.   
1 µg/µl of purified proteasomes (5 µl) were incubated at 25°C in 15 µl Buffer A (50 mM 
Tris [pH7.5], 100 mM NaCl, 10% glycerol, 1 mM DTT) plus 10 µl 5X ATP (10 mM ATP, 50 
mM MgCl2, 5 mM DTT in Buffer A) for 5 min.  20 µl of T7-tagged ubiquitinated Sic1
PY was 
added to each sample (prepared as described by Saeki et al. (31)), incubation at 25 °C continued 
for the indicated time points.  At each time point 10 µl aliquots were taken, reaction was stopped 
by addition of 6X sample buffer and boiling. To quantify data, images were acquired using a 
Gbox imaging system (Syngene) with GeneSnap software. Images were analyzed for the 
volumes in similar T7-antibody positive areas of the gel lanes using the Genetool analysis 
software from Syngene.  Volume value at t=0 was set at 100% and relative amounts of signal 
remaining at different timepoints were averaged, using 3 to 5 independent experiments and 
plotted in a graph.  
 Cell lysis, in vivo degradation assay, and immunoblotting.   
For detection of ubiquitinated substrates, cultures were grown overnight and the cell 
equivalent to 5ml of OD600 1 was collected and lysed in 100 μl sample buffer and analyzed by 
SDS-PAGE, using a 14% gel.  Degradation of Flag-ornithine decarboxylase (ODC) was 
measured as previously described (32), with minor modifications.  Briefly, transformed cells 
were grown overnight; 5 ODs of cells were lysed in sample buffer and analyzed on a 10% SDS-
PAGE.  Flag-ODC abundance was revealed by Western blot. 
 Ecm29 recruitment assay.   
4 ml of overnight culture pellets from strains, with and without proteasome tags, were 
lysed in 400 μl total lysis buffer (50 mM Tris-HCl [pH 8], 5 mM MgCl2; 1 mM EDTA; protease 
inhibitors mix) in the presence of ATP or apyrase.  To purify the proteasomes, lysates were 
incubated with IgG resin for 1 hr at 4 °C. The resin was washed three times with lysis buffer 
with or without ATP, followed by two washes with TeV buffer (50 mM Tris [pH7.5], 50 mM 
NaCl; 5 mM MgCl2; 0.5 mM EDTA; 1 mM DTT) with or without ATP. Next, the resin was 
incubated in the presence of TeV protease for 30 min at 30 °C.  After centrifugation, sample 
buffer was added to the supernatant, boiled, and analyzed by western blot.  To look at the 
degradation of Ecm29 by wild-type proteasomes, the same procedure was followed with the 
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addition of proteasome inhibitors, 100 μM tosyl-lysylchloromethane (TLCK) and 100 nM 
epoxomicin (ENZO Life Sciences, NY). 
 ATPase activity assay.   
Purified proteasomes (10 g) were incubated in reaction buffer (50 mM Tris pH7.5, 5 
mM MgCl2), and 0.5 mM ATP at 30 °C in a total volume reaction of 100 ml.  For each time 
point 20 μL of the reaction were taken, boiled for 2.5 minutes, and kept on ice.  After all the time 
points were collected, the samples were centrifuged at RT at 13,000 g for 1 min.  ADP-Glo 
Kinase (Promega, CA) assay was performed following manufacturers recommendation using a 
384-well plate.  5 μL of each sample was incubated with 5 μL of ADP-Glo reagent for 40 
minutes at room temperature.  Following this incubation, 10 μL of kinase detection reagent were 
added to each sample, and incubated for 60 minutes at room temperature.  Luminescence was 
read using the Victor 2 Microplate Reader (Perkin Elmer, MA). 
 Crosslinking.   
Purified proteasomes (1 µg/µL) were incubated in phosphate buffer (50 mM phosphate-
buffer [pH 7.2], 5 mM MgCl2, 1 mM EDTA, 1 mM ATP) with 0.25 mM Disuccinimidyl 
tartarate (DST) for 15 minutes at 30 ºC.  The reaction was quenched by adding 50 mM Tris-HCl 
[pH 7.5], followed by addition of 200 µL Urea buffer (8M Urea, 300 mM NaCl, 100 mM 
phosphate buffer [pH 7.9]).  25 µL of Talon resin (pre-equilibrated in urea buffer) was added to 
each sample, followed by 45 minutes rotation at room temperature.  Resin was washed three 
times with urea buffer.  25 µL 2x sample buffer was added and each samples was boiled for 8 
minutes prior to analysis by gel electrophoresis. 
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Table 3.1 Yeast Strains 
Strain Genotypea (lys2-801 leu2-3, 2-112 ura3-52 his3-200 trp1-1) Figure Source 
    
SUB61 MAT  3.1 (A, B, and D), 3.2, 3.3, 
3.8 
Ref. 60 
sDL133 MATa rpn11::RPN11-TEVProA (HIS3) 3.1C, 3.6, 3.8A Ref. 17 
sDL135 MATα pre1::PRE1-TEVProA (HIS3) 3.4A and B Ref. 17 
sMK141 MATα ecm29::TRP 3.1 (A, B, and D), 3.2, 3.8 This study 
sJR211 MATα ecm29::TRP rpn11::RPN11-TEVProA (HIS3) 3.6, 3.8C This study 
sJR239 MATα nas6::TRP rpn14::HYG 3.1 (A, B, and D), 3.2 Ref. 11 
sJR245 MATA hsm3::KAN 3.2 Ref. 11 
sJR301 MATA nas6::TRP rpn14::HYG ecm29::TRP 3.1 (A, B, and D), 3.2 Ref. 26 
sJR494 MATα alpha3::alpha3∆N alpha7::alpha7∆N 3.4C Ref. 61 
sJR502 MATα nas2::NAT hsm3::KAN 3.1 (A, B, and D), 3.2 This study 
sJR504 MATA rpt5:: rpt5Δ1 (HYG) 3.1 (A, B, and D), 3.2, 3.8 This study 
sJR544 MAT ecm29::TRP rpt5::rpt5∆3 (HYG) 3.1 (A, B, and D), 3.2 Ref. 26 
sJR546 MATA hsm3::KAN ecm29::TRP rpt5::rpt5∆3 (HYG) 3.1 (A, B, and D), 3.2 Ref. 26 
sJR548 MATA rpt5::rpt5Δ3 (HYG) ecm29::TRP rpn11::RPN11-TEVProA (HIS3) 3.1C, 3.5, 3.6C Ref. 26 
sJR552 MATA rpt5::rpt5Δ3 (HYG) rpn11::RPN11-TEVProA (HIS3) 3.1C, 3.5 Ref. 26 
sJR555 MATA rpt5:: rpt5Δ0 (HYG) 3.8 Ref. 26 
sJR556 MATA rpt5::rpt5Δ3 (HYG) 3.1 (A, B, and D), 3.2, 3.8 Ref. 26 
sJR558 MATA hsm3::KAN rpt5::rpt5Δ3 (HYG) 3.1 (A, B, and D), 3.2 Ref. 26 
sJR568 MATA nas2::NAT hsm3::KAN ecm29::TRP 3.1 (A, B, and D), 3.2 This study 
sJR570 MATα ecm29::TRP rpt5::rpt5∆1 (HYG) 3.1 (A, B, and D), 3.2 This study 
sJR619 MATA rpn11::RPN11-TEVProA (HIS3) 3.7 This study 
sJR649 MATA rpt5::rpt5∆3 (HYG) 3.3B This study 
sJR651 MATα ecm29::KAN rpt5::rpt5∆3 (HYG) 3.3B This study 
sJR686b MATα rpt5::rpt5Δ3 (HYG) alpha3::alpha3∆N alpha7::alpha7∆N 3.4C This study 
sJR706 MATA pre11::pre1-TeV-ProA (HIS3) alpha3::alpha3∆N 3.4 This study 
sJR736 MATA rpn11::RPN11-TEVProA (HIS3) GDPp-HIS7-ECM29::NAT 3.6, 3.7 This study 
sJR743 MATα alpha3::alpha3∆N alpha7::alpha7∆N ecm29∆ 3.4C This study 
sJR744 MATα rpt5::rpt5Δ3 (HYG) alpha3::alpha3∆N alpha7::alpha7∆N ecm29∆ 3.4C This study 
a) All strains have the DF5 background genotype ( lys2-801 leu2-3, 2-112 ura3-52 his3-Δ200 trp1-1) 
 
 
 
 Results 
Ecm29 inhibits degradation of ubiquitinated substrates.  
In vitro, the presence of Ecm29 causes reduced hydrolysis of the artificial peptide 
substrate suc-LLVY-AMC by the 26S proteasome (23,26). Therefore, we speculated that Ecm29 
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functions as an inhibitor of the 26S proteasome inside the cell. To test this, we transformed a 
wild-type strain and an ECM29-deletion strain (ecm29Δ) with a plasmid encoding the well-
characterized unstable substrate ubi-K-β-galactosidase (33). While we saw a trend of reduced 
accumulation of β-galactosidase activity in lysates of ecm29Δ cells, this reduction was not 
significant (Fig. 3.1A). However, because only a subset of proteasomes contain Ecm29 in wild-
type cells (23,26,27), any Ecm29-dependent effects may be masked. Therefore, we decided to 
utilize a previously characterized proteasome hypomorph, the rpt5-∆3 strain, in which 26S 
proteasomes are enriched with Ecm29 (Fig. 3.1B and (26)). The mutation in this strain results in 
a deletion of the last three amino acids of the proteasomal AAA-ATPase subunit Rpt5. These 
residues are important for Rpt5 binding to the CP (34,35) as well as the RP-chaperone Nas2 (26). 
Their absence conferred canavanine sensitivity, typically observed in proteasome hypomorphs 
(Fig. 3.2). rpt5-∆3 mutants showed accumulation of  β-galactosidase and high levels of β-
galactosidase activity in total lysate (Fig. 3.1A), indicating reduced proteasome activity in these 
cells. Deletion of Ecm29 from rpt5-∆3 mutants alleviated the degradation defect (Fig. 3.1A, lane 
5 and 6). Because the deletion of Ecm29 did not result in increased proteasome levels (Fig. 3.1A 
Rpt5) and Ecm29 was bound to 26S proteasomes (Fig. 3.1B and (26)), this strongly suggests 
that inhibition of proteasomes by Ecm29 in the rpt5-∆3 background contributed to the 
accumulation of β-galactosidase activity. To confirm that the observed inhibition by Ecm29 is a 
direct effect on proteasomal degradation of ubiquitinated proteins, we analyzed the ability of 
wild-type, rpt5-∆3, and rpt5-∆3 ecm29Δ-derived proteasomes to degrade ubiquitinated Sic1PY in 
vitro (31). rpt5-∆3-derived proteasomes showed a dramatic reduction in their capacity to degrade 
this substrate, and the absence of Ecm29 restored the degradation of ubiquitinated Sic1PY, 
although not back to the levels of wild-type proteasomes (Fig. 3.1C and see below).  
 
To determine if the observed inhibition by Ecm29 is specific for this proteasome 
hypomorph or a more general phenomenon, we tested the nas6∆ rpn14∆ strain. This strain, 
which contains deletions for two RP-chaperones involved in assembly of the proteasome base, 
showed canavanine sensitivity (Fig. 3.2 and (11)), and exhibited an enrichment of Ecm29 on 26S 
proteasomes (Fig. 3.1B). nas6∆ rpn14∆ cells showed an accumulation of β-galactosidase 
compared to wild-type (Fig. 3.1A), and deletion of ECM29 in this background reduced β-
galactosidase levels. Thus, Ecm29 can inhibit proteasomes in a variety of mutant strains. 
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Like the majority of proteasome substrates, ubi-K-β-galactosidase relies on ubiquitination 
for its targeting to and degradation by the proteasome. When blotting for ubiquitinated proteins 
in total lysate, we observed a general accumulation of ubiquitinated material in the proteasome 
hypomorphs (Fig. 3.1D). The deletion of ECM29 in these different backgrounds strongly 
reduced the levels of accumulated ubiquitinated proteins, indicating that Ecm29 inhibited the 
degradation of a broad range of endogenous ubiquitinated substrates inside the cell (Fig. 3.1D). 
Interestingly, this effect was also observed for wild-type cells deleted for ECM29. This suggests 
that Ecm29 inhibits at least a subset of wild-type proteasomes under normal physiological 
conditions as well.  
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Figure 3.1 Ecm29 inhibits the degradation of ubiquitinated proteins in vivo and in vitro. 
(A) Indicated strains were transformed with an unstable form of the enzyme β-galactosidase 
(Ub-K-βgal). β-galactosidase activity was measured in lysates and activities relative to wild-type 
were plotted (upper panel). Standard deviations were determined using three independent 
experiments.  Lower panels show levels of β-galactosidase enzyme using immunoblotting (anti-β-
Gal), levels of Ecm29 (anti-Ecm29), proteasome levels (anti-Rpt5) and a loading control (anti-
Pgk1). (B) Cultures from indicated strains where lysed using a French press.  Whole cell lysates 
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were subjected to native page electrophoresis in the presence of ATP and stained for Suc-LLVY-
AMC hydrolytic activity in the presence of 0.02% SDS.  Gels where analyzed by Western blot 
using an anti-Ecm29 antibody. * Indicates a non-specific background band. (C) Purified 
proteasomes were incubated with ubiquitinated Sic1PY for the indicated time.  Levels of 
ubiquitinated Sic1PY remaining were determined by immunoblotting using an anti-T7 antibody. 
Right panel shows quantification of western based on three independent experiments with T=0 
normalized as 100% and standard errors shown.  (D) Whole cell lysates from wild-type and 
mutant strains were analyzed by western blot using an anti-ubiquitin antibody.   
 
 
 
 
 
 
Figure 3.2 Deletion of Ecm29 rescues canavanine sensitivity of proteasome mutants. 
Strains with the indicated mutations or genes deleted were spotted in 4-fold dilutions on 
arginine-lacking SD plates with or without 1.5 g/ml canavanine and grown at 30 °C for 7 days.  
Dilution assays were performed in triplicates for two or more independent clones, each showing 
similar growth patterns.  
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Ecm29 inhibits degradation of the ubiquitin-independent substrate ODC.   
If inhibition of the proteasome is specific for ubiquitinated proteins, as has been reported 
for Ubp6 (18), Ecm29 could potentially be interfering with the delivery or processing of 
ubiquitinated substrates, instead of inhibiting proteasomes more directly. Therefore, we tested 
the ability of the rpt5-∆3 and rpt5-∆3 ecm29Δ strains to degrade an established, short-lived, 
ubiquitin-independent substrate, ornithine decarboxylase (ODC) (32,36,37). We transformed 
strains with a plasmid containing a Flag-tagged version of mouse ODC (32) and determined the 
steady-state level of ODC (Fig. 3.3A and B). As expected, ODC was barely detectable in lysates 
from wild-type cells. However, it accumulated in rpt5-∆3 lysates or upon treatment with 
proteasome inhibitors at concentrations that inhibit proteasome activity in wild-type cells (38) 
(Fig. 3.3A and B). Deleting ECM29 in the rpt5-∆3 background strongly reduced the 
accumulation of ODC (Fig. 3.3B), albeit not back to wild-type levels. The latter suggests that the 
rpt5-∆3 proteasomes have an intrinsic degradation defect.  This is consistent with the 
observations in the in vitro degradation assay (Fig. 3.1C) as well as the residual accumulation of 
ubiquitinated material in total lysate of rpt5-∆3 ecm29Δ cells compared to wild-type cells (Fig. 
3.1D). Nevertheless, the presence of Ecm29 is a major contributor to the reduced capacity of 
cells rpt5-3 cells to degrade ODC. 
 
To assess the role of Ecm29 under proteasome stress conditions in vivo, we tested 
canavanine sensitivity for the different strains. Canavanine is an analog of arginine that leads to 
misfolding of proteins upon incorporation into nascent proteins. To handle the extra protein 
folding stress, cells show an increased dependence on molecular chaperones and the activity of 
protein degradation machinery. The mutants that accumulated β-galactosidase (Fig. 3.1A), like 
the rpt5-∆3 and the nas6Δ rpn14Δ strains, also displayed increased sensitivity to canavanine 
(Fig. 3.2). Deletion of ECM29 in these backgrounds reduced the sensitivity to canavanine, 
consistent with a role for Ecm29 as a proteasome inhibitor in the cell (Fig. 3.2). Note that for 
certain proteasome-related mutants, like nas2Δ hsm3Δ (Fig. 3.2) and blm10Δ (39), canavanine 
sensitivity is actually augmented by the deletion of ECM29. This pleiotropic effect most likely 
indicates additional roles performed by Ecm29 in the cell (see discussion).  Nevertheless, the 
rescue of canavanine sensitivity by the deletion of ECM29 reiterates the point that, besides the 
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proteasomal mutations themselves, Ecm29 is a major contributor to degradation defects in 
certain mutants. 
 
 
Figure 3.3 Ecm29 inhibits protein degradation of ubiquitin-independent substrates in vivo. 
(A) Wild-type cells transformed with a plasmid expressing Flag-tagged mouse ODC were 
inoculated at OD ~0.5 and grown for 6 hours in the presence or absence of proteasome inhibitor 
(100 mM PS-341), lysed, and analyzed for the levels of ODC by immunoblotting using anti-Flag. 
(B) Indicated strains were transformed with a plasmid expressing Flag-tagged mouse ODC, 
grown overnight, lysed, and steady state levels of ODC were determined by immunoblotting with 
an anti-Flag antibody.  
 
 In vitro inhibition of degradation requires the CP gate.  
We have previously reported that in vitro the Ecm29-dependent inhibition of suc-LLVY-
AMC peptide cleavage was eliminated by the addition of 0.02% SDS (26). For free CP, this level 
of SDS has been shown to open the CP gate required for substrate entry (40), suggesting that 
Ecm29 prevents full opening of this gate. To test this directly, we used a mutant with a (partial) 
open-gate, the α3ΔN strain (40).  A proteasome purification in the presence of ATP yields 26S 
proteasomes with and without Ecm29. In yeast only Ecm29-containing proteasomes are stable in 
the absence of ADP and ATP (17,22,26). Therefore, to obtain only Ecm29-containing 26S 
proteasomes, we purified proteasomes in the absence of nucleotide (Fig. 3.4A) or treated 
proteasomes purified in the presence of ATP with apyrase, which hydrolysis ATP and ADP (Fig.  
3.4B). All of the resulting 26S proteasomes (Fig. 3.4A and Fig. 3.4B lane 2, 4, 6, and 8) contain 
Ecm29. As seen before, wild-type Ecm29-containing 26S proteasomes are inhibited, because 
they do not show activity in the absence of SDS (Fig. 3.4A lane 1 and Fig. 3.4B lane 2). 
67 
However, Ecm29-containing 26S proteasomes from the open-gate mutant are active (compare 
Fig. 3.4A lanes 1 and 2, Fig. 3.4B lanes 2 and 6), indicating that Ecm29-dependent inhibition 
requires a functional CP gate. Immunoblotting for Ecm29 and CP subunit α7 as well as the 
hydrolytic assay in the presence of SDS showed that similar levels of 26S proteasome were 
present in the native gel. In sum, Ecm29 inhibition of suc-LLVY-AMC hydrolysis depends on a 
functional CP-gate, indicating that binding of Ecm29 to 26S proteasomes reduces the time these 
proteasomes spend in an open-gate conformation.  
To test if Ecm29 in vivo mainly acts through regulation of the gate, we compared 
accumulation of the unstable substrate β-galactosidase (see Fig. 3.1A) in an open-gate mutant 
strain with or without the rpt5-∆3 mutation. To ensure maximal disruption of the gate we used a 
strain containing deletions of the N-terminus of two alpha subunits, both α3 and α7 (40). The 
increased accumulation of substrate in the rpt5-∆3 background was Ecm29 dependent (Fig. 
3.4C). Thus, in vivo the inhibition by Ecm29 is not eliminated by disruption of the CP gate, 
indicating Ecm29 inhibits proteasomes through a gate independent mechanism as well.  
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Figure 3.4 The open-gate mutant rescues Ecm29-dependent inhibition of Suc-LLVY-AMC 
hydrolytic activity in vitro, but not the Ecm29-dependent inhibition of in vivo substrates. 
Proteasomes were affinity-purified from strains with tagged CP subunit in the absence of ATP to 
ensure all 26S proteasomes are associated with Ecm29 (22).  The samples were subjected to 
native gel electrophoresis in the presence of ATP and stained for suc-LLVY-AMC hydrolytic 
activity in the presence or absence of 0.02% SDS. Ecm29 containing 26S proteasomes from the 
open-gate mutant (α3∆N), but not wild-type cells, show suc-LLVY-AMC hydrolytic activity in the 
absence of SDS. The addition of SDS shows both preps contain 26S proteasomes with Suc- LLVY-
AMC hydrolytic capacity. Immunoblotting of the native gels for Ecm29 and the CP subunit α7 show equal 
amounts of Ecm29 on the proteasome preparations. (B) Proteasomes were affinity-purified from strains 
with tagged CP subunit in the presence of ATP. To visualize the difference between RP-CP species with 
or without Ecm29, samples were treated with apyrase to remove all ATP and ADP. In apyrase treated 
samples all 26S proteasomes are associated with Ecm29 as shown previously (22,26). The samples were 
subjected to native gel electrophoresis in the presence of ATP and stained for suc-LLVY-AMC hydrolytic 
activity in the presence or absence of 0.02% SDS. Wild-type and mutant proteasomes show reduced 26S 
activity upon apyrase treatment, because only a small fraction of proteasomes contain Ecm29. Wild-type 
Ecm29-containing proteasomes have reduced activity in the absence of SDS (compare top panel lane 2 
and 4). The open-gate (3N) Ecm29-containing proteasomes do not show increased activity upon 
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addition of SDS (compare lane 6 and 8), indicating that in vitro Ecm29 requires a functional gate for 
inhibition of suc-LLVY-AMC hydrolysis. Immunoblotting of native gels for Ecm29 and the CP subunit 7 
show equal amounts of Ecm29 on the proteasome preparations with or without apyrase treatment.   (C) 
Open-gate mutant (α3∆N α7∆N) does not rescue the accumulation of β-galactosidase as a result of the 
rpt5-∆3 mutations. Assay identical to Fig. 1A.  
 
 Ecm29 reduces proteasomal ATPase activity of rpt5-∆3.  
Unlike peptide substrates, the degradation of folded protein substrates in vivo as well as 
in vitro is ATP dependent. Therefore, we tested if Ecm29 affects proteasomal ATPase activity. 
We purified proteasomes from rpt5-∆3 cells using a wash step with 25 mM or 200 mM NaCl 
(Fig. 3.5A). The high salt wash reduces Ecm29 levels, because the proteasomal association of 
Ecm29 is salt sensitive (17,23). Consistent with the reported role of Ecm29 as a stabilizer of 26S 
proteasomes (17,22), proteasomes with reduced levels of Ecm29 showed reduced anmounts of 
CP subunits (Fig. 3.5A, bands between 17 and 23 kDa). However, the level of proteasomal 
ATPases was similar (Fig. 3.5A lower panel). Proteasome preparations washed with 200 mM 
NaCl showed an increased ATPase activity (Fig. 3.5B). This suggests the presence of Ecm29 
inhibits the proteasomal ATPase activity. To further test this, we purified proteasomes from rpt5-
∆3 and rpt5-∆3 ecm29Δ strains under low salt conditions.  As expected the deletion of Ecm29 
resulted in less CP (Fig. 3.5C, bands between 17 and 23 kDa). SDS-PAGE analysis, 
immunoblotting, as well as mass spectrometry analysis show, however, similar levels of RP and 
proteasomal ATPase subunits (Fig. 3.5C and table 3.2). To measure the ATPase activity from 
these preparations, we again measured ADP production over time (Fig. 3.5D). As shown in Fig. 
3.5E, we observed increased ATPase activity in proteasome preparations that lack Ecm29. The 
mass spectrometry analysis does not show any other ATPases in the sample that could explain 
the difference in ATPase activity (Table 3.2). Furthermore, the observed ATPase activity shows 
reversed correlation with the amount of Ecm29 present (Fig. 3.5) and the observed ATPase 
activities are within the same range as reported by others for proteasomal ATPase activity (41). 
Therefore, our data strongly suggest that Ecm29 –directly or indirectly– inhibits proteasomal 
ATPases.  
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Figure 3.5 Ecm29 inhibits proteasomal ATPase activity from rpt5-∆3 derived proteasomes. 
(A) Coomassie Blue stained SDS-PAGE analysis of proteasome preparations that were purified 
using affinity-tagged lid subunit Rpn11 and washed with buffer containing different 
concentrations of NaCl. Lower panel shows levels of the ATPases subunit Rpt4 by 
immunoblotting (anti-Rpt4).  (B) ATPase activity for purifications from (A). The activity was 
determined by measuring ADP produced over time. Data show average ATPase activity with 
standard deviation for triplicates of two independent purifications. Activity measurements have 
been repeated with similar results. Difference in activity was significant with p < 0.05 as 
determined by student t-test. (C) Coomassie Blue stained SDS-PAGE analysis of proteasome 
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preparations that were purified using affinity-tagged lid subunit Rpn11. Lower panel shows 
levels of the ATPases subuunit Rpt4 by immunoblotting  (anti-Rpt4).  (D + E) ATPase activity for 
purifications from (C). The activity was determined by measuring ADP produced over time. Data 
show average ATPase activity with standard deviation for triplicates of two independent 
purifications. Activity measurements have been repeated with similar results and are within the 
range previously reported for proteasomal ATPases (41). Difference in activity was significant 
with p < 0.05 as determined by student t-test. 
 
Ecm29 inhibits wild-type proteasomes.  
As we relied on proteasome mutants for the enrichment of Ecm29 onto proteasomes, the 
observed effects might be unique for the specific mutant used. The reduced accumulation of 
ubiquitinated proteins in total lysate of the ecm29 strain suggests, however, that Ecm29 has the 
same effect on wild-type cells (Fig. 3.1C). To test this more rigorously, we generated a strain that 
strongly overexpresses Ecm29 by replacing the endogenous promoter with the GPD promoter 
(29). This has been shown to cause increased Ecm29 levels onto wild-type proteasomes (23). 
Next, we affinity-purified proteasomes from an ecm29 strain, a strain with the endogenous 
promoter, or a strain overexpressing Ecm29 (Fig. 3.6A). The ATPase activity measured in these 
purifications again showed a reversed correlation with Ecm29 levels present; the 
ecm29derived proteasomes showed increased ATPase activity and the purifications with 
increased levels of Ecm29 showed reduced ATPase activity (Fig. 3.6B).  Thus, association of 
Ecm29 with proteasomes results in reduced ATPase activity independent of the presence of 
proteasome mutations. To test if the increased presence of Ecm29 on wild-type proteasomes also 
results in degradation defects we measured, as we did for rpt5-∆3 derived proteasomes (Fig. 
3.1C), the ability of wild-type proteasomes enriched in Ecm29 to degrade ubiquitinated Sic1PY. 
Consistent with a function as inhibitor of the proteasome, we observed slower degradation of 
Sic1PY in the presence of Ecm29 (Fig. 3.6C). The overexpression of Ecm29 also caused modest 
canavanine sensitivity (Fig. 3.6D). These data further confirm that the presence of Ecm29 on 
proteasomes results in reduced ATPase activity and interferes with the ability of proteasomes to 
degrade substrates.  
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Figure 3.6 Ecm29 inhibits wild-type proteasomes. 
(A) Coomassie Blue stained SDS-PAGE analysis of proteasome preparations from indicated 
strains that were purified using affinity-tagged lid subunit Rpn11. Lower panel shows levels of 
the ATPases subunit Rpt4 by immunoblotting (anti-Rpt4).   (B) ATPase activity for purifications 
from (A). The activity was determined by measuring ADP produced over time. Data show 
average ATPase activity with standard deviation for triplicates of two independent purifications. 
Activity measurements have been repeated with similar results and are within the range 
previously reported for proteasomal ATPases. Difference in activity between samples was 
significant with p < 0.05 as determined by student t-test. (C) Purified proteasomes from 
indicated strains were incubated with ubiquitinated Sic1PY for the indicated time.  Levels of 
ubiquitinated Sic1PY were determined by immunoblotting using an anti-T7 antibody.  Right panel 
shows quantification of western based on three independent experiments with T=0 normalized as 
100% and standard errors shown. (D) Over-expression of Ecm29 results in modest canavanine 
phenotype.  Strains with ECM29 deletion or Ecm29 over-expression were spotted on SD plates 
lacking arginine with or without 1.5 g/ml canavanine in 4-fold dilutions and grown for 7 days 
at 30 °C (SD plates). 
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 Ecm29 binds close to the regulatory particle subunit Rpt5.  
Ecm29 has been proposed to bind to CP as well as RP, however, no detailed binding 
information is available for Ecm29 (17). To identify a proteasomal binding site for Ecm29 we 
generated a strain that contains an N-terminally His-tagged  Ecm29 in a background containing 
the Rpn11-tev-ProA with or without the rpt5-∆3 mutation. Proteasomes purified from both 
strains using the Rpn11-ProA tag show a similar subunit composition and the presence of Ecm29 
(Fig. 3.7A). To identify a direct binding partner, or proteasome subunit in close proximity of 
Ecm29, we treated the purified proteasomes with crosslinker (DST, 6.4Å spacer arm length). 
Samples with or without crosslinking were denatured in 8 M urea and His-Ecm29 was purified 
under denaturing conditions. Samples were resolved on SDS-PAGE and stained with Coomassie 
(Fig. 3.7B). Lanes 3 and 5 specifically show slower migrating bands, likely indicating Ecm29 
crosslinked to a proteasome subunit. Mass spectrometry analysis of gel region with crosslinked 
material revealed the presence of Ecm29 and Rpt5 in lanes 2 and 4, but not lanes 1, 3, or a 
control sample that was crosslinked but lacked His-tagged Ecm29. Western blot analysis of the 
different steps in the procedure confirmed Rpt5 crosslinking to Ecm29 (Fig. 3.7C). Considering 
the moderate levels of crosslinking (Fig. 3.7B and 3.7C), the crosslinking between Rpt5 and 
Ecm29 is likely direct. This is also consistent with previous work detecting more Ecm29 in 
proteasomes purified using tagged-Rpt5 (42). In sum, our data show that Ecm29 either binds 
Rpt5 directly or binds in close proximity to Rpt5.  
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Figure 3.7 Ecm29 binds close to the AAA-ATPase subunit Rpt5. 
(A) Coomassie Blue stained SDS-PAGE analysis of proteasome preparations from indicated 
strains that were purified using affinity-tagged lid subunit Rpn11.  (B) Samples from (A) were 
treated with the crosslinker DST or DMSO, denatured in 8 M urea and His-Ecm29 was purified 
using Talon resin.  Sample was resolved on gel and stained with Coomassie Blue. (C) 
Immunoblots are shown for Rpt5 and Ecm29 in the different steps of the crosslinking procedure. 
Lane 3 and 8 show Rpt5, as would be expected, crosslinked to several different proteasome 
subunit. Crosslinking was not excessive as ~50% of the Rpt5 was not crosslinked, hence amounts 
of indirect crosslinking should be low. The purification under denaturing conditions in lanes 5 
and 10 show the specific crosslinking to Ecm29. 
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Table 3.2 Peptide numbers of proteins identified by Mass Spectrometry 
            rpt5-∆3   rpt5-∆3 ecm29∆ 
       
Ecm29  ECM29_YEAST  211610  89  0 
         
alpha1  SCL1_YEAST  25759  23  11 
alpha2  PRE8_YEAST  27145  12  5 
alpha3  PRE9_YEAST  31688  10  4 
alpha4  PRE6_YEAST  28697  15   
alpha5  PUP2_YEAST  28770  21  5 
alpha6  PRE5_YEAST  28154     
alpha7  PRE10_YEAST  28650  10   
         
beta1  PRE3_YEAST  26968  17  3 
beta2  PUP1_YEAST  22560  6   
beta3  PUP3_YEAST  22819  6   
beta4  PRE1_YEAST  29425  20  6 
beta5  PRE2_YEAST  31902  11  6 
beta6  PRE7_YEAST  23761  15  3 
beta7  PRE4_YEAST  28650  4  4 
         
Rpt1  CIM5_YEAST  52293  27  24 
Rpt2  YTA5_YEAST  49026  17  12 
Rpt3  YTA2_YEAST  47864  22  17 
Rpt4  SUG2_YEAST  49492  15  13 
Rpt5  YTA1_YEAST  48283  26  22 
Rpt6  SUG1_YEAST  45471  20  14 
         
Rpn1  RPN1_YEAST  109880  52  51 
Rpn2  RPN2_YEAST  104623  58  55 
Rpn3  RPN3_YEAST  60754  29  24 
Rpn5  RPN5_YEAST  51850  29  16 
Rpn6  RPN6_YEAST  50085  31  26 
Rpn7  RPN7_YEAST  49213  29  16 
Rpn8  RPN8_YEAST  38460  25  20 
Rpn9  RPN9_YEAST  45811  31  27 
Rpn10  RPN10_YEAST  29786  13  7 
Rpn11  RPN11_YEAST  34433  19  11 
Rpn12  RPN12_YEAST  31956  26  15 
Rpn13  RPN13_YEAST  18005  6  7 
         
Nas6  NAS6_YEAST  25616  12  10 
Ubp6  UBP6_YEAST  57110  40  27 
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Hul5  HUL5_YEAST  105564  16  8 
         
Ssa2  SSA2_YEAST  69469  4  5 
Hsp70       63400   2   0 
Ecm29 recruitment to the proteasome.  
The enrichment of Ecm29 on mutant proteasomes can in part be explained by increased 
expression of Ecm29 under proteasome stress conditions (23). However, this cannot explain why 
we consistently observed an increased presence of Ecm29 on proteasomes purified in the 
absence of nucleotide as compared to proteasomes purified with ATP present (Fig. 3.8A; apyrase 
was used to remove endogenous ATP and ADP from lysates). This difference cannot be 
explained by ATP-dependent degradation of Ecm29 during the purification, because this 
accumulation was not observed in the presence of ADP or in the presence of proteasome 
inhibitors (Fig. 3.8A). Thus, Ecm29 appears to be specifically recruited to proteasomes with 
most or all ATPase subunits in a nucleotide-empty state.  
 
To test if Ecm29 enrichment on proteasomes in specific strains, like the rpt5-∆3, can be 
explained in part by a preferential binding of Ecm29 to such proteasomes, we tried to purify 
Ecm29 from bacteria. However, bacterial-expressed full-length Ecm29 was unstable and not 
competent in binding to proteasomes; therefore, we used a lysate of wild-type yeast cells as our 
source of Ecm29. To test if this Ecm29 has a preference for binding to certain proteasomes, we 
looked at the recruitment to affinity-tagged proteasomes from wild-type or rpt5-∆3 strains 
deleted for ECM29 (Fig. 3.8B).  We observed that more Ecm29 associated with rpt5-∆3-derived 
proteasomes as compared to the wild-type (Fig. 3.8C).  Treatment with apyrase enhanced the 
amount of Ecm29 bound to wild-type as well as rpt5-∆3-derived proteasomes, but retained 
Ecm29’s preference for mutant proteasomes (Fig. 3.8C). Strong overexpression of Ecm29 can 
also yield increased Ecm29 levels on wild-type proteasomes ((23) and Fig. 3.6), suggesting that 
the subtle difference in affinity regulates Ecm29 abundance on proteasomes. Consistent with 
this, more modest overexpression of Ecm29, like we observed in our control or Rpt5 truncated 
strains (Fig. 3.8D) only shows a modest increase of proteasome-associated Ecm29 in the control 
strain, while there is a strong increase for the Rpt5 truncation strains (Fig. 3.8E). In all, these 
experiments show that Ecm29 preferentially binds to nucleotide-depleted proteasomes as well as 
rpt5-∆3-derived proteasomes.   
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Figure 3.8 Ecm29 recognizes aberrant proteasomes. 
(A) Proteasomes from wild-type cells were purified in the presence of ATP, ADP, or in the 
absence of these nucleotides (apyrase was used to convert endogenous ATP and ADP to AMP) 
using an affinity tag on the lid subunit Rpn11. Levels of co-purified Ecm29 were determined by 
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immunoblotting for Ecm29 (anti-Ecm29). Proteasome levels were determined using an antibody 
against the proteasome subunit Rpt5. To show that the enrichment in the absence of nucleotide 
was not due to proteasomal degradation, the same experiment was performed in the presence of 
proteasome inhibitors (100 μM tosyl-lysylchloromethane and 100 nM epoxomicin). Table shows 
relative Ecm29 levels, corrected for input and normalized to lane 1. (B) Schematic of experiment 
in panel C. Wild-type lysates (middle) provide a source of Ecm29 and are mixed with lysates 
from ecm29∆ cells containing Rpn11-ProA tagged proteasomes  (left) or ecm29∆ rpt5-∆3 cells 
containing Rpn11-ProA tagged proteasomes (right).  After incubation, proteasomes are affinity 
purified using IgG resin, separated on SDS-PAGE, and analyzed. (C) Experimental scheme, as 
described in B, was performed in the presence of ATP or in the absence of nucleotide (apyrase). 
Samples were analyzed for the levels of recruited Ecm29 and Rpt5 was used as a loading 
control. Results show enriched binding of Ecm29 in the absence of nucleotide as well as to the 
rpt5-∆3 proteasomes. Table shows relative Ecm29 levels, corrected for input and normalized to 
lane 1. (D+E) Levels of proteasome associated Ecm29 and total cellular levels. Cultures from 
wild-type and mutant strains where lysed using a French press.  (D) Whole cell lysates were 
subjected to SDS-PAGE followed by immunoblotting for the indicated proteins. (E) Whole cell 
lysates were subjected to native page electrophoresis in the presence of ATP and stained for Suc-
LLVY-AMC hydrolytic activity in the presence or absence of 0.02% SDS.  Next, Gels were 
analyzed by Western blot using an anti-Ecm29 antibody. * indicates a non-specific background 
band, as it is also observed in the ecm29 background.  
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 Discussion 
Since its discovery as proteasome-associated protein over ten years ago, many functions 
have been proposed for Ecm29. This probably indicates that Ecm29 has multiple functions inside 
the cell. Consistent with this, the deletion of ECM29 in the different mutant strains shows 
pleiotropic effects. As mentioned in the results, canavanine sensitivity can either be augmented 
or rescued when ECM29 is deleted.  For temperature stress, the deletion of ECM29 has been 
observed to increase (e.g. ump1Δ strain (27)) as well as rescue (e.g. the rpt6-Δ1 or the nas2Δ 
hsm3Δ strains (23,26)) temperature sensitivity. Interestingly, for the nas2Δ hsm3Δ strain deletion 
of Ecm29 shows a very robust rescue of the temperature sensitivity (26), while at the same time 
it shows a modest increase in canavanine sensitivity (Fig. 3.3). Clearly, different phenotypes in 
specific mutants each highlight a different cellular function of Ecm29.  
 
In this study we utilized a proteasome hypomorph, the rpt5-∆3 strain, to study the 
function of Ecm29 in cells, because Ecm29 is highly enriched on 26S proteasomes in this strain 
(26). Surprisingly, our data show that the proteasomal degradation defect in this proteasome 
hypomorph is only partly due to the mutation of the proteasome subunit Rpt5. The increased 
presence of Ecm29 on proteasomes in this strain is a major contributor to this strain’s inability to 
degrade proteasome substrates. Several other proteasome mutants also show an increase in 
Ecm29-bound proteasomes (23,27). As the mutations to proteasome subunits likely cause the 
formation of aberrant proteasomes, Ecm29 might have a more common role as inhibitor of 
proteasome activity for certain aberrant forms of the proteasome.  
 Proteasomal recruitment of Ecm29. 
How would Ecm29 be able to be enriched on a variety of proteasome mutants, while in 
wild-type cells only a subset of proteasomes are associated with Ecm29 (22,23,26-28). One 
proposed model suggests that Ecm29 is degraded by the proteasome (27). If proteasome mutants 
have reduced proteolytic activity Ecm29 would then accumulate. This model is supported by the 
observation that affinity-tagged Ecm29 is unstable (27,28). However, untagged Ecm29 has been 
reported to be stable (23), suggesting an alternative mechanism for Ecm29 enrichment on 
proteasomes. A second model proposes that an increase in the ratio Ecm29 versus proteasomes 
in specific proteasome mutants is a determining factor in proteasomal association of Ecm29 (23). 
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Consistent with this, the overexpression of ECM29 from a very strong promoter increases the 
association of Ecm29 to wild-type proteasomes (Fig. 3.6 and (23)). However, this model 
provides little dynamic control if Ecm29 is a stable protein and seems counterintuitive 
considering the inhibitory function described here. Furthermore, such a model cannot explain the 
preferential binding we observe (Fig. 3.8C), or the increase in Ecm29 recruitment upon oxidative 
stress (24). We propose that an important component of the recruitment of Ecm29 to 
proteasomes relies on the ability of Ecm29 to recognize –directly or indirectly– certain aberrant 
conformations of the proteasome.  
 
Mutants in RP as well as CP have been shown to cause increased Ecm29 association. It 
seems unlikely that Ecm29 would be able to recognize differences in the conformation induced 
by proteasome mutants located at distant or opposite sites of the proteasome. We speculate that 
Ecm29 does not recognize each mutant specifically, but all these mutants cause a similar 
unfavorable alignment between CP and RP that results in increased affinity for Ecm29 to 
proteasomes.  For certain mutants, like rpt5-∆3 or rpt6-∆1, it is clear that they affect the CP-RP 
interface, since the C-terminal residues deleted in these mutants dock into pockets located on the 
alpha ring surface of the CP and contribute the to RP-CP interaction (13,34,35,43-47).  Ecm29 
also has been reported to recognize RP-CP species in which CP maturation is stalled (27). 
Ecm29 might recognize those by a different mechanism, because, at first glance, it appears 
unlikely that stalled CP maturation affects the RP-CP interface. However, the proteolytic active 
sites of the CP have been shown to allosterically affect the RP-CP interface (22,48). This 
suggests that certain CP mutations or the level of CP maturation could affect the conformation of 
the RP-CP interface.  
 
The model that Ecm29 recognizes differences at the CP-RP interface is also supported by 
the observed increase in binding of Ecm29 to nucleotide-depleted proteasomes (Fig. 3.8). Under 
normal conditions, only two of the proteasomal AAA-ATPase subunits have been suggested to 
be free of nucleotides (49). The lack of more nucleotides probably causes a different 
conformation of the ATPase ring that abuts the CP, since the lack of nucleotide is known to 
destabilize the RP-CP interaction (22). The increased association of Ecm29 to nucleotide-
depleted proteasomes, suggests Ecm29 recognizes such proteasomes prior to the RP-CP 
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dissociation.  Another protein showing nucleotide dependent binding is AIRAP. This protein is 
not present in yeast, but C. elegans AIRAP has been shown to preferably bind and stabilize 
nucleotide depleted proteasomes (50). However, unlike Ecm29, AIRAP seems to increase suc-
LLVY-AMC hydrolytic activity of the proteasomes with which it associates (50). 
 
Our crosslinking of Ecm29 to Rpt5 is consistent with the model we propose as well as 
with recent cryo-EM structures of the proteasome. The latter show that Rpt5 is accessible for 
binding (51-54). Considering the large size of Ecm29 (210 kDa) and the unique binding 
properties (only binds to 26S proteasomes) we expect Ecm29 will interact with additional 
proteasome subunits. Identifying the other proteasomal binding sites of Ecm29 will further 
establish how the specificity of binding by Ecm29 is achieved.  
 
The recruitment of Ecm29 to certain aberrant proteasomes fits well with previous reports 
proposing a function as a quality control protein (26,27). A tantalizing model is that the 
inhibition of the proteasome is an important component of Ecm29’s quality control function, as it 
prevents proteolysis by aberrant proteasomes from occurring inside the cell.  Next, such 
proteasomes would have to be either corrected or targeted for degradation, e.g. by the lysosome. 
The former has been suggested (27), while the latter might provide a connection to other 
proposed functions of Ecm29 by linking it to endosomes and transport motors (21,25). Clearly, a 
better understanding of the fate of Ecm29-bound proteasomes will be crucial to understand the 
role of Ecm29 in proteasome assembly, quality control and regulation.   
 Mechanism of inhibition by Ecm29. 
Since recent EM structures of the proteasome (51-54) indicate that access to the CP gate 
is shielded by the Rpt subunits, it seems unlikely that Ecm29 can directly inhibit CP gate 
opening. Our data show that Ecm29 binds to the proteasome in close proximity to Rpt5. Thus, 
Ecm29 might restrict the conformational freedom of one or several of the proteasomal Rpt 
proteins thereby causing reduced ATPase activity. The binding to Rpt5 might also cause closing 
of the CP-gate, since the Rpt proteins abut the CP and are known to regulate gate opening 
(34,35,43,44). Furthermore, mutations disrupting ATP binding or hydrolysis in yeast and 
mammalian proteasomal ATPases have been shown to affect gating and protein degradation (55-
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57). Alternatively, binding of Ecm29 to the CP directly might induce an allosteric closing of the 
gate. In this scenario, the inhibition of ATPase activity and gate closing are two independent 
events induced by Ecm29 binding to RP and CP respectively.   
 
Understanding the mechanism of Ecm29-proteasome interactions might provide us with 
new targets in the search for alternative proteasome inhibitors and shows, as had previously been 
shown with USP14, that targeting the RP has the potential for the development of 
pharmaceuticals (19,58).  More intriguingly, the realization that Ecm29 is an in vivo inhibitor of 
proteasome activity might provide new clues towards reduced proteasome activity observed in 
certain neurodegenerative diseases and during ageing (59). It will be interesting to see if there is 
increased binding of KIAA00368/ECM29 to proteasomes in such conditions. 
 
 
 
A.D.L.M., S.Y.L, and J.R. conceived the experiments, S.Y.L performed experiments in 
figure 8. A.D.L.M conducted all other experiments with assistance or materials provided by B.P 
(Fig. 1, 6 and 7), P.W. (Fig. 4) and C.R.S (Fig. 1C and 7). A.D.L.M. , S.Y.L. and J.R. analyzed 
and interpreted the data. A.D.L.M. and J.R. wrote the manuscript with input from all coauthors.  
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Proper proteostasis is important for human health, as its disruption is linked to cancer, 
neurodegeneration and aging.  At the cellular level this is achieved through tightly regulated 
quality control networks.  These networks function from the moment a protein is being 
synthesized, until the protein is targeted for degradation.  The ubiqutin-proteasome pathway is 
the major pathway of selective protein degradation in the cell. Here the proteasome is the end 
point, where actual protein degradation happens.   Since many cellular processes rely on 
selective degradation of proteins, understanding this pathway can provide many insights into 
cellular functions and homeostasis.  In addition to that, the UPS has become a major target for 
translational research. The ability of regulating selective protein degradation is critical to many 
diseases, and the ubiquitin-proteasome pathway provides multiple points of regulation.   Many 
efforts are underway to develop inhibitors for different steps in the UPS, from E1 ubiquiting-
activating enzymes all the way to the proteasome (30).  One important aspect in understanding 
proteasomal protein degradation is to elucidate how to regulate the proteasome.  The studies into 
how this molecular machine assembles have provided new insights into proteasome function, 
and suggest that the assembly process can actually provide many targets for control (36).   
The work described in this dissertation focuses on understanding the assembly of the 
proteasome by studying the interactions between the AAA-ATPase Rpt5 with the chaperone 
Nas2, and the quality control protein Ecm29. Rpt5 is an important subunit of the 26S 
proteasome, it is one of the ATPases involved in the unfolding of substrates and it is at the 
interface between RP and CP. Results show that Nas2 requires the last three amino acids of the 
Rpt5 tail for binding (15). These three amino acids are part of the unstructured 12-amino acid C-
terminal tail, which has been reported to dock onto CP and induce opening of the substrate 
access gate and activate hydrolysis (6, 33).  These results suggest that having Nas2 bound to the 
tail would directly prevent docking into the CP. A similar function has been shown for the other 
RP chaperones, Hsm3, Nas6 and Rpn14, which bind to the C-domain of their respective Rpt, but 
do not require the last amino acids of the tail, suggesting they inhibit binding to the CP by 
creating steric hindrance (4, 23, 24, 26).  Considering that unlike Hsm3, Nas6 and Rpn14, Nas2 
departs from assembly intermediates early in assembly, preceding full ATP ring formation, these 
results would imply that it is also important early in assembly to prevent the association of RP 
subunits with the CP. 
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Surprisingly, in addition to reduced binding of Nas2 in the mutant proteasomes, we 
observed increased binding of another proteasome-associated protein, Ecm29.  Ecm29 has been 
reported as a stabilizing factor for the RP-CP interaction in the absence of ATP (14, 16). 
However, more recent publications suggest it is also a negative regulator or quality control 
protein for proteasome assembly (17, 21, 37).   Proteasomes purified form Rpt5 mutant strains 
enriched in Ecm29 remained stable when ATP was removed from the system, as previously 
reported (14, 16).  Nevertheless, these proteasomes displayed reduced suc-LLVY-AMC 
hydrolytic activity. Hydrolytic activity was restored in the presence of small amounts of SDS.  
Since SDS can artificially open the CP gate, this suggests that Ecm29 was inhibiting opening of 
the gate.  The tail of Rpt5 is needed for opening of the gate, hence it could be argued that the 
reason why the gate is failing to open is due to the tail mutation of Rpt5, however deletion of 
ECM29 from the Rpt5 mutant relieved the degradation defects. Additionally, strains with 
mutations in different proteasome subunits that were also enriched in Ecm29, showed similar 
results (22). Our in vivo data confirmed that indeed Ecm29 inhibits the degradation of 
ubiquitinated as well as non-ubiquitinated substrates (3).  Thus, besides stabilizing proteasomes, 
Ecm29 also inhibits their function. Additionally, consistent with its proposed function in quality 
control of the proteasome, our results show that Ecm29 preferentially binds to mutant and ATP-
depleted proteasomes.  Depletion of ATP (in vitro) results in disassociation of the RP-CP, recent 
studies into the structure of the 26S suggest the ATPase ring goes through conformational 
changes when ATP is bound, these changes affect the RP-CP interaction and substrate unfolding 
and translocation through the catalytic pore (2, 18, 34). Based on our findings, we propose that 
Ecm29 recognizes non-native conformations in assembled proteasomes. These conformations are 
either derived from ATP depletion on in vitro studies, or from mutations in proteasome subunits.  
The binding of Ecm29 to these somewhat “faulty” proteasomes, leads to inhibition of 
proteasomal activity, thereby ensuring no aberrant degradation of proteins occurs in the cell. The 
two functions we observe for Ecm29 in the proteasome, stabilizing (a positive interaction) and 
inhibiting (a negative interaction), can seem contradictory. However, considering Ecm29 as a 
quality control mechanism of proper proteasome assembly and function, these properties might 
be in place to ensure that only properly formed 26S can degrade cellular proteins and prevent 
aberrant degradation. 
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Ecm29 is a 210 kD protein and it’s known to bind to both RP and CP. Through 
crosslinking and mass spectrometry we were able to identify Rpt5 as a binding partner for 
Ecm29 in the RP. Ecm29 stabilizes RP-CP interaction, which implies there is a binding site for 
Ecm29 on the CP as well.  Future studies should focus on finding additional binding sites for 
Ecm29 in both the RP and CP, which will help draw a better picture of the mechanisms of 
inhibition of Ecm29.  Based on the current data we propose that when there are no defects in the 
proteasome, the binding sites of Ecm29 in RP and CP are not positioned to allow high affinity 
binding of the Ecm29 molecule (Fig 4.1A). However, when there are structural misalignments of 
the RP-CP interface (Fig 4.1B), the Ecm29 binding sites on the RP and CP are repositioned in a 
way that allows for high-affinity binding of Ecm29 with the proteasome.    
We are currently working on identifying the binding site for Ecm29 on the CP.  
Additional studies to test our hypothesis will include mutating the binding sites on CP or RP, and 
assess how this affects the interaction with Ecm29, as well as the inhibitory function of Ecm29 
on the proteasome. 
Interestingly, our phenotypic data, using the Rpt5 mutants together with Hsm3, Nas2 and 
Ecm29 deletion mutants, suggests that there are additional functions to both Nas2 and Ecm29 in 
assembly of the proteasome. If the only function of Nas2 is to prevent docking of Rpt5 onto CP, 
deleting NAS2 from strains that are defective in Rpt5 docking should cause no additional 
phenotypes.  However, deletion of Nas2 in such a background exacerbates the phenotype (Fig. 
2.3).   
Consistent with this, recently published structure data from our lab (32) shows that the 
Nas2 protein structure has patches that are conserved from yeast to humans. We believe these 
patches could be important for conserved protein-protein interactions, which go beyond the 
interaction between the Nas2 PDZ domain and the Rpt5 tail (29). 
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Figure 4.1 Proposed model of Ecm29 binding to proteasomes 
 
We hypothesize that Nas2 could be working as a scaffold, facilitating the formation of 
specific intermediate assembly complexes, and preventing the formation of off-pathway 
complexes.   Figure 4.2 illustrates these idea, where the RP chaperones function not only to 
prevent the docking into the CP, but also function in preventing premature binding of 
intermediate complexes.  The chaperones exist in subcomplexes with one or more RP subunits 
(e.g. Hsm3-Rpt1-Rpt2-Rpn1, Nas2-Rpt5-Rpt4) (1, 24, 27, 35), supporting this hypothesis. 
However, additional studies into how the subcomplexes come together could confirm that the 
chaperones serve as scaffolds for the assembly.  
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Figure 4.2 Model for chaperone function in RP assembly (2). 
 
Our phenotypic analysis data also suggests a role for Ecm29 in assembly, something that 
has been proposed by other groups (17, 21, 22).  We found that deletion of Ecm29 in particular 
RP-chaperone mutant combinations could not be explained by Ecm29 inhibitory activity.  
Deletion mutants of Nas6/Rpn14 and Hsm3/Nas2 are known to have phenotypes at 37ºC (12, 
26).  The deletion of Ecm29 has no effect on the on the Nas6/Rpn14 mutant, but rescues 
Hsm3/Nas2. Interestingly, when we look at the phenotypes of these strains in canavinine, the 
deletion of Ecm29 was able to rescue the Nas6/Rpn14 phenotype, but exacerbated the phenotype 
of Hsm3/Nas2.  When looking for phenotypes of proteasome mutant strains, growth analyses at 
37ºC or with canavinine are often used indistinctively. However, our data together with 
phenotypic analysis of other strains (e.g. Ubp6∆)(11, 28) suggests phenotypes at 37ºC are 
representative of proteasome assembly defects, whereas the phenotypes in canavinine are 
representative of proteasome function defects.  With this in mind, our data suggests an additional 
function for Ecm29 in assembly of the proteasome.  Additional studies with a bigger array of 
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strains would be required to confirm our observations into the differences in phenotypes at 37ºC 
and canavinine.  
With this work we have reported Ecm29 to be an inhibitor of the proteasome as part of its 
quality control functions.  A lot of questions remain to be answered, first, what happens with the 
proteasomes that are enriched in Ecm29.  Work in mammalian cells links Ecm29 to the 
endosomes (7, 8, 9), which has led us and other groups (36) to speculate that these proteasomes 
are transported to endosomes with the help of Ecm29, and eventually are degraded by the 
lysosome. 
The chaperones, as well as the proteasome subunits, and Ecm29 are conserved among 
eukaryotes, retaining their functions from yeast to humans.  In recent years there have been many 
reports using mammalian systems, where the RP chaperones Nas6 (Gankyrin), Hsm3 (S5b) and 
Rpn14 (PAAF1) have been implicated in regulation of proteasomal function, and linked to 
diseases that range from cancer to HIV (13, 19, 31, 39).  Interestingly, recent studies suggest a 
direct relationship between levels of Rpt1 and tumor growth in some cancers.  Here the loss of a 
copy of the gene that encodes for Rpt1 (PSMC2) rendered the tumors specifically sensitive to 
Rpt1 shRNA (20).  In yeast, overexpression of Rpt1 rescues Hsm3 mutant phenotypes and vice 
versa (5, 26), considering that deletion of Rpt1 is lethal, it would be of interest to look at the 
effect of manipulating the levels of Hsm3 in these cancer cells.  In general, there is increased 
evidence suggesting roles for the proteasome chaperones in regulation of the proteasome, with 
the proteasome fast becoming an important drug target for treatment of diseases (10, 25, 30, 38). 
Understanding the different functions of Nas2 and Ecm29 can be of critical importance. For 
example, it would be of great relevance to know if the inhibitory function of Ecm29 in the 
proteasomes is conserved in higher organisms.  If so, the impact on the development of 
treatments for neurodegenerative diseases, and the afflictions of ageing would be great, since 
there are reports of lower proteasomal activity in these conditions. 
Finally, figure 4.3 summarizes the findings of our studies into the role of Rpt5 in 
proteasome assembly and function.  Like every other process in the cell, the assembly of the 
proteasome is subjected to multiple levels of quality control.  First, during assembly of the RP 
there are multiple chaperones, including Nas2, that prevent premature docking onto CP, as well 
as prevent premature binding of subcomplexes.  Once the proteasome is assembled, there is a 
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second quality control checkpoint, where Ecm29 senses conformational defects in the 
proteasome and binds to the “faulty” proteasomes inhibiting their activity. 
 
 
 
Figure 4.3 Model for quality control of proteasome assembly and function. 
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Appendix A - Identification of the atypical extracellular  
regulated kinase 3 (Erk3) as a novel substrate for p21-activated 
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 Abstract 
The Class I p21-activated kinases (Pak1, -2, -3) regulate many essential biological processes, 
including cytoskeletal rearrangement, cell cycle progression, apoptosis and cellular 
transformation.  While many Pak substrates, including elements of mitogen-activated protein 
kinase (MAPK) signaling pathways, have been identified, it is likely that additional substrates 
remain to be discovered.  Identification of such substrates, and determination of the 
consequences of their phosphorylation, is essential for a better understanding of Class I Pak 
activity.  To identify novel Class I Pak substrates we used recombinant Pak2 to screen high-
density protein microarrays.  This approach identified the atypical MAPK Erk3 as a potential 
Pak2 substrate.  Solution based in vitro kinase assays using recombinant Erk3 confirmed the 
protein microarray results, and phospho-specific antisera identified serine 189, within the Erk3 
activation loop, as a site directly phosphorylated by Pak2 in vitro.  Erk3 protein is known to 
shuttle between the cytoplasm and the nucleus, and we showed that selective inhibition of Class I 
Pak kinase activity in cells promoted increased nuclear accumulation of Erk3.  Pak inhibition in 
cells reduces the extent of Erk3 phosphorylation and inhibits the formation of Erk3/Prak 
complexes.  Collectively, our results identify the Erk3 protein as a novel Class I Pak substrate 
and further suggest a role for Pak kinase activity in atypical MAPK signaling. 
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 Introduction 
The Class I p21-activated kinases (Pak1, -2, -3) are established effectors of the small 
GTPases Rac1 and Cdc42 (1).  Although initially discovered as regulators of the actin 
cytoskeleton, they have subsequently been implicated in a variety of different signaling pathways 
including those that control proliferation, apoptosis and transformation (2, 3). Not surprisingly, 
misregulated Pak kinase activity is associated with a variety of different pathological conditions 
(4-6). As Pak kinase activity contributes to a large number of different signaling pathways 
understanding the specific role for Paks in any biological response is greatly aided by the 
identification of the protein(s) they phosphorylate and the consequences of these 
phosphorylations.  Although the list of Pak kinases substrates is quite large (3, 7), we are 
particularly interested in how Pak kinases modulate mitogen-activated protein kinase (MAPK) 
signaling cascades as these cascades are important for gene expression, cell proliferation and 
programmed cell death (8). 
 
MAPK signaling is one of the most evolutionarily conserved signal transduction 
pathways and is critical for many biological responses (9). Various cellular stimuli lead to the 
phosphorylation and activation of a family of serine/threonine kinases known as MAP3Ks, 
initiating a three-tiered kinase cascade. Activated MAP3Ks phosphorylate and activate specific 
MAP2Ks.  MAP2Ks are dual-specificity kinases that phosphorylate threonine and tyrosine 
residues within the activation loop of the MAPKs (the conserved T-X-Y motif) to activate them; 
phosphorylation of both activation loop residues is required for MAPK activation. Activated 
MAPKs then transphosphorylate a variety of different proteins including structural proteins, 
enzymes, and transcription factors that ultimately drive the appropriate cellular response to the 
initial signal (10).   
In some signaling pathways the substrates for MAPK activity are themselves kinases and 
are defined as MAPK-activated kinases (MAPKAKs or MKs) extending the characteristic three-
tiered architecture (11).  
 
Although the central roles of the MAP3Ks, MAP2Ks and MAPK isoforms to signaling 
pathways are incontrovertible, the intensity and duration of MAPK signaling is additionally 
regulated by the activity of non-canonical proteins, including Paks.  Pak kinase activity promotes 
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Erk1/2 signaling at two distinct points: Pak phosphorylation of the MAP3K c-Raf on serine 338 
cooperates with Src-dependent phosphorylation at tyrosine 341 for maximal c-Raf kinase activity 
(12), and Pak phosphorylation on serine 298 of Mek1facilitates the interaction of Mek1 with 
Erk2 (13). 
 
 In addition to the classical MAPK families (ERK, p38 and JNK/SAPK), many cells also 
express atypical MAPK isoforms characterized by the Erk3, Erk4, Nlk (nemo-like kinase) and 
Erk7/8 proteins (14).  Erk3 and 4 are most closely related to the Erk1 MAPK isoform, sharing 45 
and 42% amino acid identity respectively with the catalytic domain of Erk1.  Despite this 
similarity, Erk3 is incapable of phosphorylating known Erk1/2 substrates in vitro (15).  One of 
the key characteristics that distinguish Erk3, Erk4 and NLK from the classical MAPK isoforms 
is the lack of the characteristic “T-X-Y” motif within their activation loops.  In Erk3 and Erk4 
the corresponding sequence is S-E-G, and for Nlk it is T-Q-E (14).  Although Erk7 does contain 
a T-X-Y sequence that is phosphorylated in vivo, this phosphorylation is not catalyzed by any 
known MAP2K but results from autophosphorylation (16).  As such, Erk7 is also generally 
considered a member of the atypical MAPK family (14). 
 
 Unlike the classical MAPKs, dual phosphorylation of the Erk3/Erk4 activation loops is 
not possible. It is formally possible that S189 phosphorylation of Erk3 could result from a 
MAP2K since Mek2, but not Mek1, poorly phosphorylated Erk3 S189 in vitro (17).  However, 
using a cell-fractionation approach to identify the kinase responsible for Erk3 S189 
phosphorylation, the Cobb laboratory identified a S189 kinase that did not co-fractionate with 
Erk1/2 kinase activity, excluding Mek1/2 from consideration as cellular Erk3 kinases (18).  A 
similar approach based on the strong affinity of the Erk3 kinase for recombinant Erk3 excluded 
protein kinase C as the cellular S189 kinase despite the ability of PKC to phosphorylate Erk3 in 
vitro (18). The initial observation of Erk3 S189 phosphorylation in vivo occurred more than a 
decade ago (18) but the kinase(s) responsible for this phosphorylation remains unidentified.  
 
Using high-density protein microarrays, we identified Erk3 as a potential Pak2 substrate. 
Pak2 kinase assays using recombinant full-length Erk3 protein in solution confirmed the protein 
microarray results and suggested that Erk3 is a direct p21-activated kinase substrate in vitro. We 
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further demonstrated that Pak2 directly targets the S189 site, within Erk3’s activation loop, 
suggesting that p21-activated kinases contribute to Erk3 activation and furthermore may 
represent the elusive Erk3 S189 kinase (referred to as Kinase X in (19)).  A variant of Erk3 
lacking this phosphorylation site (S189A) displays an increased nuclear accumulation in 
fibroblasts, which can be phenocopied by wild type Erk3 with selective inhibition of Class I Pak 
kinase activity. Furthermore, expression of a selective Pak inhibitor in cells reduced the levels of 
Erk3 S189 phosphorylation.   As phosphorylation of this site stabilizes the interaction of Erk3 
with its effector Prak, we also demonstrated using Pak inhibitors and S189A and 189D variants 
of Erk3 that Pak kinase inhibition is sufficient to disrupt the interaction between Erk3 and Prak 
in cells. Collectively, our results identified Erk3 as a novel substrate for Class I Pak kinase 
activity and identified S189, within the Erk3 activation loop, as a residue phosphorylated by 
Class I kinase activity in vitro and in vivo suggesting a role for class I p21-activated kinases in 
regulating the subcellular localization and activity of the atypical MAPK Erk3. 
 
 Experimental Procedures 
Human Protein Microarrays 
Kinase Substrate Identification (KSI) ProtoArrays (version 4.0 arrays containing 8,274 
full-length GST fusion proteins provided by Invitrogen) were processed as recommended by the 
manufacturer with the following modification: the supplied kinase buffer was replaced with 1X 
phosphobuffer (20). Recombinant His6-Pak2 expressed from E.coli was used as the exogenous 
kinase.  This source of Pak2 is known to be constitutively active (Beeser and Chernoff 
unpublished observation) obviating the need for inclusion of Rac/Cdc42-GTP. “No-kinase” 
slides were identically processed in parallel as the Pak2 slides except they lacked Pak2. 
Radiographic images of the slides were obtained using a Fuji phosphorimager and spots were 
identified using GenePix Pro (Molecular devices).  Data analysis was conducted in ProtoArray 
Prospector v.2.0 software as recommended (Invitrogen).  For overlay images, spots were 
pseudocolored in Adobe Photoshop. 
Plasmids and Plasmid Construction  
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The human Erk3 vector was kindly provided by Dr. Sylvain Meloche, University of 
Montreal.  The Erk3 sequence was cloned into the N-terminal His6 baculovirus transfer vector 
pFBHTB (Invitrogen) and used to make high- titer baculovirus stocks (P4) as recommended. For 
mammalian expression vectors, the human full-length Erk3 ultimate ORF Gateway entry clone 
was purchased from Invitrogen, and moved to the N-terminal GFP (pcDNA6.2-EmGFP-N) and 
the N-terminal His6 (pDest26) Gateway destination vectors using the LR Clonase II enzyme mix 
as recommended (Invitrogen).  Site directed point mutants of Erk3 (S189A, S189D) were created 
using the Erk3 ultimate ORF plasmid as template and Quick change II kit (Stratagene) with the 
following mutagenic oligonucleotides: SA1  (5’-cattattcccataagggtcatcttgctgaaggattggttactaaat-
3’), SA2 (5’-atttagtaaccaatccttcagcaagatgacccttatgggaataatg-3’), SD1 (5’-
ctcattattcccataagggtcatcttgatgaaggattggttactaaatgg-3’), SD2 (5’-
ccatttagtaaccaatccttcatcaagatgacccttatgggaataatgag-3’). Plasmids encoding only the desired 
S189A or S189D mutations were identified by DNA sequencing and were then moved to 
pcDNA6.2-EmGFP-N and pDest26 vectors as described above.   GFP-PID (corresponding to 
amino acids 83-149 of human Pak1) and GFP-PIDLl07F constructs were amplified by 
polymerase chain reaction using human Pak1 and Pak1L107F expression constructs as template 
and subsequently cloned into pEGFP-C1 (Clontech). mRFP-PID constructs were constructed by 
Pfusion (NEB) polymerase chain reaction using the above PID vectors as templates and the 
following oligonucleotides 5’-gcggatggatgcacacaattcatgtcggttttgat-3’ and 5’-
gcgaattcctatttatctgtaaagctcatgtattt-3’.  The PCR products were digested with BamHI and EcoRI 
restriction enzymes, purified from 1X TBE/agarose gels and ligated into pCS2+mRFP-N1 (a gift 
from Dr. Chris Thorpe, Kansas State University) similarly digested followed by DNA sequence 
confirmation. 
Purification and Dephosphorylation of Recombinant Erk3  
High titer P4 stocks were used to infect suspension cultures of Sf21 cells maintained in 
SFM-900 III media (Invitrogen).  48 hours post infection the cultures were pelleted by 
centrifugation, the supernatant discarded and the pellet was either frozen at -80 C or 
immediately resuspended in 30 ml of lysis buffer (15 mM NaHPO4, 300 mM NaCl, 10 mM 
imidazole pH 8.0 containing 1mM PMSF, 1:100 aprotinin (Fisher) and 200 l protease inhibitor 
cocktail (Pierce)).  The pellet was subjected to 6-8 rounds of 30-second sonication, 30 seconds 
105 
on ice. The lysate was centrifuged for 10 minutes at 15000 rpm at 4°C in a SS-34 rotor.  The 
cleared lysate was transferred to a 50 ml conical tube followed by addition of HisPur beads 
(Pierce) pre-equilibrated in lysis buffer and rotated for 1 hour at 4C.  The beads were collected 
by 3000-rpm centrifugation in a swinging bucket rotor Sorvall H1000B (5 min at 4C) and 
washed 3X with lysis buffer lacking PMSF and protease inhibitors.  The protein was eluted from 
the beads with lysis buffer containing 200 mM imidazole for 4 hours at 4C.  The 200 mM 
imidazole eluate containing Erk3 was concentrated using a Viva Spin 15R 30 000 molecular 
weight cut off (MWCO) centrifugal concentrator as recommended (Sartorius). The retentate was 
dialyzed against 10% glycerol/ 1 X Tris buffered saline (TBS) at 4C overnight; then divided 
into single-use aliquots in 1.5 ml microfuge tubes and frozen at -80°C.  
Western analyses 
Protein samples were resolved on SDS-PAGE mini-gels, and transferred to PVDF 
membranes as recommended (BioRad).  Membranes were blocked in 1X TBST, 5% BSA 
(Fisher) for greater than one hour at room temperature. All primary antibodies were incubated at 
4C overnight in blocking buffer.  Primary antibodies used included TheHis-Tag mAb 
(Genscript A00186), total Erk3 (Cell Signaling # 4067), Erk3 phospho S189 (Abgent AP3098a), 
Prak (Santa Cruz sc-46667) and GFP (Cell signaling #2555). HRP- linked secondary antibodies 
were from Cell Signaling.  Signal detection used the Immobilon Chemiluminescent HRP 
substrate (Millipore).  
 In vitro Pak2 kinase assays 
The Erk3 protein stock was dialyzed into 1X phosphobuffer using a 10 000 MWCO mini 
Slide-a-lyzer (Pierce).  0, 1, 5, 10, 15 or 20 ul of the Erk3 protein were brought up to a final 
volume of 30 l containing 100 M ATP (final concentration) and 0.25 Ci of 32P-ATP (NEN).  
Where indicated, 11 ng of recombinant His6-Pak2 was added.  As a positive control for Pak2 
kinase activity myelin basic protein (MBP, Upstate) was included at a final concentration of 0.17 
g/ml under identical conditions. Kinase assays were allowed to proceed for 30 minutes at 30C 
followed by cooling on ice, the addition SDS-PAGE loading buffer to 1X followed by boiling for 
5 minutes.  Samples were resolved on 10 % acrylamide SDS-PAGE Gels, equilibrated into 40% 
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acetic acid/10% methanol, dried onto Whatmann 3MM paper under vacuum and exposed to 
phosphorimager screen (Cyclone, Perkin Elmer). 
Cell culture and treatments 
NIH3T3 and HEK293 cells were obtained from the ATCC.  All growth media, serum and 
supplements were purchased from Hyclone.  NIH3T3 cells were grown in 1X DMEM + 10% 
calf serum supplemented with penicillin/streptomycin. HEK293 cells were grown in 1X MEM + 
10% fetal bovine serum supplemented with penicillin/streptomycin.  Cells were grown at 37C, 
5% CO2 in a humidified chamber. NIH3T3 cells were transfected with 2ug DNA in a 6-well plate 
using Arrest-In transfection reagent as recommended (Open Biosystems).  24 hours post 
transfection cells were split into 4-well slides (LabTek) and allowed to attach overnight.  Cells 
were fixed in 3.7% formaldehyde (in 1X PBS) for 20 min at room temperature, washed with PBS 
pH7.4, and permeabilized using 0.2% Triton X (in 1X PBS) for 10 min at room temperature.  
Cells were washed 3X in 1X PBS and DAPI (Roche) was added for 5 minutes prior to addition 
of ProLong antifade reagent (Invitrogen).  Fluorescent images were acquired from a Nikon 
eclipse E600 microscope equipped with a Qimaging QiCAM camera using Qcapture Pro 
software. 
HEK293 Lysis and Immobilized Metal Affinity Chromatography  
For His6-Erk3 pull downs, HEK293 cells in 100 mm plates were transfected with 5g of 
plasmid DNAs using TransIT-293 reagent (Mirus) or in 6 well plates with the Profection 
Calcium Phosphate method (Promega). 48 hours post transfection cells were lysed in RIPA 
buffer containing 10 mM imidazole, 1mM sodium orthovanadate, 0.5% sodium deoxycholate, 10 
mM -glycerophosphate, 5 mM sodium pyrophosphate, 50 mM sodium fluoride, 1mM PMSF 
and 1:100 aprotinin (Fisher).  Lysates were centrifuged at 21000xg for 10 minutes at 4C. 
Cleared lysate protein concentrations were determined by BCA assay (Pierce) and equilibrated 
with lysis buffer.  HisPur beads (Pierce) were added to the cleared lysate and incubated with 
end/end rotation at 4 C overnight.  The beads were washed twice with lysis buffer, brought to 
100 l total volume in lysis buffer followed by addition of 20 l 6 X SDS-Page sample loading 
buffer. 
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 Results 
High-density Protein Microarrays Identify Erk3 as a Potential Pak2 Substrate.   
Although the list of validated substrates for the p21-activated kinases is quite extensive 
(2, 21) it is likely that additional substrates remain to be identified.  To identify novel Pak kinase 
substrates we used constitutively active recombinant Pak2 to screen a high-density protein array. 
The protein microarrays (KSI slides, Invitrogen) contain 8274 full-length human proteins 
including fiduciary kinases that serve as orientation landmarks spotted in duplicate onto 
microscope slides. Similar arrays have been used to identify novel substrates for a variety of 
different protein kinases, including Cdk5 (22) and the A. thaliana MAPKs Mkp3 and Mkp6 (23).  
A summary of the proteins identified from the protein microarrays is presented in appendix 
Figure 1.  In addition to identifying proteins previously implicated involved in Rac-dependent 
signaling (i.e ARHGEF5 and ARHGAP15), we also identified the atypical MAPK Erk3 as a 
potential Pak2 substrate (Fig. A.1, Fig. A.2). The lack of a signal at the Erk3 co-ordinates in the 
no kinase slide suggested that the corresponding signal in the Pak2 kinase slide is not the result 
of Erk3 autophosphorylation and suggested that Erk3 is a Pak2 phosphoacceptor in vitro. 
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Figure A.1 High-density protein microarrays identifies the atypical MAPK Erk3 as a Pak2 
phosphoacceptor. 
A. Flow chart for Kinase substrate identification (KSI) slides (left) were processed as described 
in experimental procedures using recombinant His6-Pak2.  Statistically significant spots were 
identified in Protoarray Prospector. B.  A single block of the array from the ATP alone and ATP 
+Pak2 slides are shown at higher magnification (middle). All substrate proteins are spotted in 
duplicate, single spots or spots that do not align with the printing grid (grey circles) are 
excluded from consideration The 33P- spots obtained from the phosphorimager were 
pseudocolored, and overlaid (bottom).   Yellow signals in the overlay result from 
autophosphorylation, either by spotted protein kinases or by fiduciary kinases (FK) that are 
arrayed in the upper left and lower right of each block for orientation landmarks. Red signals 
appearing in the overlay, including Erk3, identify proteins transphosphorylated by recombinant 
Pak2 
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Figure A.2 Proteins identified as Pak2 substrates by the Kinase Substrate Identification 
(KSI) microarrays. 
Output file of protoarray prospector for ATP + Pak2 protein microarray. Each protein is spotted 
in duplicate and evaluated independently. The common name of the accession numbers, when 
known, appears at the left. 
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Pak2 Phosphorylates Full-length Erk3 in Solution.   
Although KSI slides can rapidly identify potential new kinase substrates, we wanted to 
confirm that Erk3 was a Pak2 phosphoacceptor in solution.  This is an important consideration as 
not every protein identified from protein microarrays recapitulates in solution. KSI experiments 
using recombinant p38alpha, CK2 and PKA kinases identified 26 potential substrates, 5 of which 
(19%), failed confirmation when tested in solution (Invitrogen).  Human Erk3 is an inherently 
unstable protein subject to proteasome-mediated degradation (24).  As the protein microarrays do 
not reveal which residues of Erk3 are phosphorylated, we chose to use a baculovirus expression 
system similar to what has been previously reported for expression of full-length Erk3(25) and 
Erk4 (26) (Fig. A.3A).  Although our Erk3 preparation is not homogenous, it is highly enriched 
and cross-reactive with both anti-Erk3 antisera (directed towards residues surrounding leucine 
410) and anti-His6 antibodies directed towards the extreme N-terminus of the protein (Fig. 
A.3B).  Our Erk3 preparations therefore contain presumably full-length (based on electrophoretic 
mobility) as well as discrete C-terminal truncations that do not extend beyond amino acid 410 
(Fig. A.3B).  We used this source of recombinant Erk3 for Pak2 in vitro kinase assays to confirm 
the initial protein microarray result.  As expected, in the absence of exogenous substrates 
recombinant Pak2 undergoes autophosphorylation as monitored by 32P incorporation (Fig. A.3C, 
lane 1).  Inclusion of myelin basic protein (MBP), led to both Pak2 autophosphorylation and 
MBP transphosphorylation (Fig. A.3C, lane 2).  The increased autophosphorylation of Paks by 
substrates has previously been reported (27) and we have previously observed that high 
concentrations of Paktide can lead to Pak activation independently of small GTPases (28).  
Inclusion of increasing amounts of recombinant Erk3 with a fixed amount of recombinant Pak2 
lead to an increase in the extent of Erk3 phosphorylation (Fig. A.3C, lanes 3-7, Erk3 signal is 
denoted by an asterisk).  Exclusion of recombinant Pak2 from samples containing the highest 
amount of Erk3 (Fig. A.3C, lane 8) indicated that the phospho-Erk3 signal is dependent on Pak2 
and argues against Erk3 phosphorylation resulting from autophosphorylation or by an unknown 
contaminating kinase in our Erk3 preparations. Additionally, although both the His6 and total 
ERK3 antisera reveal the presence of three major cross-reactive species, the in vitro kinase 
assays predominantly what appears to be a single phosphorylated species. We do not know 
whether this results from the inability to specifically resolve the three Erk3 species (each 
approximately 100 kDa) or whether the different C-terminal truncations have differential ability 
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to be phosphorylated by Pak2, as is the case for the phosphorylation of the C-terminal of ERK3 
by Cdk1to regulate its stability in mitosis (29). Together, these results demonstrate that Pak2 
kinase is able to selectively phosphorylate GST-Erk3 on protein microarrays (Fig. A.1 and A.2) 
and His6-Erk3 (Fig. A.3C) in vitro. 
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Figure A.3 Erk3 is a Pak2 substrate in solution 
A.  Purification scheme of recombinant Erk3 from baculovirus infected insect cells.  Cell pellets 
were collected 48 hours post infection with high-titer baculovirus stocks and lysed by sonication.  
Specific fractions were collected and evaluated for purity by electrophoresis on a 10% SDS-
Page gel followed by Coomassie staining.  Lane 1 = total cell lysate, lane 2= cleared lysate,  
lane 3= HisPur non-binding fraction, lane 4= HisPur wash1, lane 5= HisPur wash 2, lane 6= 
200 mM imidazole elution fraction,  lane 7=  Vivaspin 30 000 MWCO filtrate, lane 8=  Vivaspin 
30 000 MWCO retentate.  The asterisk denotes the slowest migrating, and presumably full-length 
Erk3.  B.  Purified ERK3 protein is recognized by N-terminal hexahistidine and total Erk3 
antibodies. Increasing amounts of the 30 000 MWCO retentate  (Fig. 2A, lane 8) were resolved 
by electrophoresis on an 8% SDS-PAGE gel and subjected to Western analyses using anti-Erk3 
(top) and anti-His6 antibodies (bottom).  C. 32P-ATP Autoradiogram of Pak2 in vitro kinase 
assays.   For all lanes the amount of Pak2 added remained constant.  Lane 1= Pak2 protein 
alone, lane 2= Pak2 + MBP, lane 3-7= Pak2 with increasing amounts of Erk3 protein.  Lane 8= 
Equivalent amounts of ERK3 as in lane 7 but lacking Pak2.  32P- Erk3 is denoted by asterisk, 
32P-Pak2 and 32P-MBP signals are also identified. 
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Pak2 Phosphorylates Erk3 on Serine 189.   
Erk3 is a member of the atypical MAPK family, lacking the characteristic “T-X-Y” motif 
within the activation loop (in Erk3, the corresponding sequence is S189-E190-G191).  Although 
the S189 site is phosphorylated in cells (18, 19) the kinase responsible for this phosphorylation 
has yet to be identified.  As Pak2 can phosphorylate Erk3 in vitro (Fig. A.1, Fig. A.3C), we 
asked whether Pak2 could specifically phosphorylate S189.  Using phospho-specific S189 
antibodies, we demonstrate that recombinant Erk3 derived from insect cells is pre-
phosphorylated at this position (Fig. A.4, lane 1), consistent with previous observations for 
recombinant full-length Erk4 purified from insect cells (26). Addition of ATP alone led to a 
small increase in the extent of the phospho-S189 signal, as did the inclusion of ATP and Pak2 
(Fig. A.4, lanes 2, 3). Although S189 cross reactivity is clearly observed in our ERK3 
preparations, we cannot determine the stoichiometry of this phosphorylation by Western blot.  In 
order to more clearly evaluate whether Pak2 can phosphorylate S189 we first dephosphorylated 
Erk3 with lambda phosphatase followed by inactivation of the phosphatase by addition of 
sodium orthovanadate.  This treatment completely abolished phospho S189 cross-reactivity (Fig. 
A.4, lane 4 top panel) without affecting the total amount of Erk3 (Fig. A.4, bottom panel).  
Addition of ATP alone to the dephosphorylated Erk3 did not promote an increase in phospho 
S189 cross-reactivity suggesting again that the increased S189 signal was not the result of Erk3 
autophosphorylation, consistent with our previous results (Fig. A.1).  Addition of Pak2 and ATP 
to the dephosphorylated Erk3 protein led to an increase in S189 phosphorylation (Fig. A.4, lane 
6).  Collectively, these results demonstrate that Erk3 is a suitable substrate for Pak2 kinase 
activity in vitro, and that at least one of the residues phosphorylated by Pak2 is serine 189. 
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Figure A.4 Pak2 phosphorylates serine 189 within the Erk3 activation loop in vitro. 
The Erk3 protein purified from insect cells is pre-phosphorylated on serine 189.  Recombinant 
Erk3 protein (Fig. 2A, lane 8) was dialyzed into 1X phosphobuffer and subjected to an in vitro 
kinase assay using recombinant Pak2.  Proteins were resolved by electrophoresis on an 8% 
SDS-PAGE gel and subjected to Western analyses using phospho-S189 specific antisera (upper 
panel) and total Erk3 antibodies (lower panel) to ensure equivalent loading of Erk3.  Lane 1= 
Erk3 protein in 1X phosphobuffer, lane 2 = Erk3 protein after 30 minutes incubation with ATP, 
Lane 3 = Erk3 protein after 30 minutes incubation with ATP and Pak2.  Lanes 4-6 are similar to 
lanes 1-3 with the exception that the Erk3 source was first dephosphorylated by lambda 
phosphatase followed by inactivation of the phosphatase by the addition of sodium 
orthovanadate. 
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Pak Kinase Inhibition Promotes Erk3 Nuclear Accumulation.   
Erk3 is known to shuttle between the nucleus and the cytoplasm through a CRM1-
dependent mechanism (30).  To determine whether S189 phosphorylation contributes to the 
localization of Erk3, we assessed the subcellular localization of GFP-Erk3, as well as the GFP-
Erk3S189A and GFP-Erk3S189D variants in transiently transfected NIH3T3 cells.  Wild type 
and S189D variants are predominantly cytoplasmic whereas the GFP-Erk3S189A variant 
displays an increased nuclear localization (Fig. A.5A, B).  To determine whether this differential 
localization was dependent on Pak kinase activity, we co- transfected NIH3T3 cells with wild 
type GFP-Erk3 and various monomeric red fluorescent protein (mRFP) constructs expressing the 
Pak1 protein inhibitory domain (PID).  The PID corresponds to residues 83-149 of human Pak1 
and acts as a highly selective pan-Class I (Pak1, -2 and -3) inhibitor when expressed in trans by 
exploiting Class I Pak’s activation mechanism (31).  Co-expression of mRFP-PID, but not mRFP 
alone or the inactive mRFP-PIDL107F, significantly increased the extent of nuclear Erk3 (Fig. 
A.5C, D).  These results implicated Pak kinase activity in regulating the subcellular distribution 
of Erk3.   
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Figure A.5 Erk3 S189 phosphorylation promotes its cytoplasmic redistribution in NIH3T3 
cells. 
A.  NIH3T3 cells were transfected with GFP tagged expression plasmids for wild type Erk3, 
Erk3S189A and Erk3S189D.  48 hours post transfection cells were fixed and counterstained with 
DAPI to unambiguously identify the nucleus. B.  Quantification of the subcellular distribution of 
Erk3.  The subcellular localization of the GFP-Erk3 signals was determined for greater than 100 
transfected cells.  Each GFP positive cell was scored blind and assigned into one of three 
categories: uniform GFP signal in the cytoplasm and the nucleus (N=C), predominantly nuclear  
(N>C) or predominant cytoplasmic staining (N<C).  C.  Inhibition of Pak kinase activity 
promotes the nuclear retention of GFP-Erk3.  NIH3T3 cells were co-transfected with wild type 
GFP-Erk3 expression plasmids and expression plasmids encoding mRFP, mRFP-PID or mRFP-
PIDL107F. 48 hours later the cells were fixed and analyzed as described above.  D, 
Quantification of the subcellular distribution of GFP-Erk3 in cells expressing the indicated 
mRFP constructs.  Bar graphs represent the mean and +/- SEM of at least three different 
transfections. 
117 
Inhibition of Pak kinase activity reduces the extent of Erk3 S189 phosphorylation in 
cells. 
Our biochemical results suggesting that recombinant Erk3 was phosphorylated by 
recombinant Pak2 and that at least one of the sites phosphorylated in vitro is within Erk3’s 
presumptive activation loop prompted us to determine whether this also occurred in cells.  As 
endogenous ERK3 is subjected to degradation by the 26S proteasome we relied on co-
transfecting HEK293 cells with plasmids encoding emGFP-ERK3 and the following  mRFP 
constructs: mRFP (empty vector control), mRFP-PID (active Class I inhibitor) or mRFP-
PIDL107F (inactive class I inhibitor). Approaches to evaluate the relative levels of S189 
phosphorylation require that the vast majority of GFP positive cells are also RFP positive which 
we confirmed by immunofluorescence (Fig.  A.6A); we estimate that the proportion of 
GFP+/RFP- transfected cells is less than 5% of the total number of GFP positive cells.   
 
  These cells were then lysed and subjected to Western blots using total Erk3 antibodies.  
Although we generally load equivalent amounts of total protein lysates for Western blots, in this 
case we had to empirically adjust the amount of lysate loaded to approach equivalent levels of 
total Erk3 protein as it appears that co-expression of the RFP-PID leads to a decrease in the 
amount of GFP-Erk3 expressed. Once conditions achieved approximate equivalent loading of 
ERK3 were achieved these same conditions were probed with the phospho S189 antibody and 
the relative S189 and total ERK3 signals were determined by densitometry.  Figure A.6B shoes 
that co-expression of the PID leads to a decrease in the extent of S189 cross-reactivity, 
quantification of three independent transfections suggests that expression of the PID can reduce 
the S189/ total Erk3 signal ratio approximately two fold.  These data suggest that selective Pak 
inhibition in cells leads to a decrease in Erk3 S189 phosphorylation and suggests that ERK3 is a 
Class I Pak substrate in cells. 
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Figure A.6 Pak kinase inhibition reduces the extent of Erk3 S189 phosphorylation in cells. 
HEK293 cells were cotransfected with expression contructs for EmGFP-Erk3 and monomeric 
RFP, monomeric RFP-PID or monomeric RFP-PIDL107F.   A. 48 hours post transfection, the 
cells were imaged on an inverted fluorescent microscope to ensure that the majority of cells 
expressing GFP-ERK3 also expressed a mRFP variant.  B.  Cell lysates were prepared from 
replicate independent transfections including cells imaged in A, and separated by 
electrophoresis prior to Western analyses with variable amounts of lysate loaded to empirically 
achieve approximately equal levels of total Erk3.  These conditions were then used to probe a 
replicate blot with the phospho S189 specific antibody.   C. The densitometric ratios of the 
phospho S189/ total Erk3 signals for three independent transfecrions were acquired in Image J  
(NIH) using recommended protocols. 
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S189 Phosphorylation Modulates the Interaction of Erk3 and Prak. 
Although the kinases responsible for S189 phosphorylation had heretofore been 
uncharacterized, site directed mutants (S189A) had previously demonstrated that S189 
phosphorylation was essential for the ability of Erk3 to interact with and activate Prak (19, 26), 
the only known Erk3 substrate. As S189 phosphorylation is required for a productive Erk3/Prak 
interaction and Pak inhibition leads to decreased S189 cross reactivity in cells (Figure A.6B), we 
asked whether Pak inhibition also led to a decreased Erk3/Prak interaction.  To address this we 
co-transfected HEK293 cells with a His6-Erk3 expression plasmid and plasmids expressing GFP, 
GFP-PID or GFP-PIDL107F.  The His6-Erk3 was adsorbed by IMAC and the extent of 
endogenous Prak co-purifying with His6-Erk3 was determined by Western analysis.  Focusing 
on the wild type allele (Fig. A.7, leftmost panels), expression of the PID, but not GFP alone or 
the inactive GFP-PIDL107F variant, reduced the amount of Prak co-precipitating with His6-
Erk3.  This was not due to reduced Prak expression as the levels of endogenous Prak in whole 
cell lysates was not affected by expression of the PID (Fig. A.6).  To ensure that the ability of 
Pak inhibition to reduce the stability of the Erk3/Prak complexes did not result from other 
residues of Erk3 being phosphorylated by Paks, we repeated the experiments described above 
using the non-phosphorylatable (S189A) and phospho-mimetic (S189D) variants of His6-Erk3.  
Consistent with the model proposed for Erk3/Prak interaction (19) mutation of serine 189 to 
alanine strongly reduced the extent of Prak co-precipitating with His6-Erk3 (Fig. A.7 middle 
panels).  Substituting serine 189 with aspartic acid restored the interaction between Erk3 and 
Prak.  Importantly, and unlike the wild type allele, the Erk3S189D/Prak interaction was 
insensitive to the expression of the PID (Fig. A.7 rightmost panels).  These results demonstrated 
that selective Class I kinase inhibition in cells modulates the interaction of Erk3 with its only 
known effector Prak, in a mechanism that is dependent on S189 phosphorylation, and provides 
the first evidence that Class I activity modulates the activity of Erk3 in cells. 
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Figure A.7 Pak kinase inhibition prevents the association of Erk3 with its known effector 
Prak in an S189-dependent manner. 
HEK293 cells were co-transfected with expression constructs for His6-Erk3, His6-Erk3S189A or 
His6-Erk3S189D along with expression constructs for GFP, GFP-PID or GFP-PIDL107F as 
indicated.  48 hours post transfection; His6 proteins were affinity adsorbed to HisPur beads.  
The amount of His6-Erk3 in the His pulldowns was determined by Western analysis using total 
anti-Erk3 antibodies and the amount of endogenous Prak was similarly determined using anti-
Prak antibodies (upper six panels).  To ensure appropriate expression of indicated GFP 
constructs and that the experimental treatments did not alter the total levels of endogenous Prak, 
Western analyses of whole cell lysates were conducted using anti-GFP and anti-Prak antibodies 
(lower six panels). Numbers on the right represent the molecular mass as determined by pre-
stained SDS-Page loading standards.  Results are representative of three independent co-
transfections. 
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 Discussion 
A number of different groups have investigated the requirements for Erk3 and Erk4 
activation loop phosphorylation and kinase activity in atypical MAPK signaling pathways.  
These pathways remain enigmatic with respect to both the cellular upstream activating signals 
(functioning analogously to MAP2Ks) and to a slightly lesser extent in regards to downstream 
effectors (the MAPK activated kinases or MKs).  Models for Erk3/Erk4 function have so far 
been generally restricted to the following common properties: i) the ability of variants of 
Erk3/Erk4 to bind to Prak ii) the ability of Erk3/Erk4 variants to promote Prak T182 
phosphorylation and/or activate the kinase activity of Prak and iii) the ability of these variants to 
modulate their own subcellular localization or the subcellular localization of Prak. 
  
 The Erk3 literature is not entirely consistent with regards to the requirements of S189 
phosphorylation and Erk3 kinase activity for Prak activation (25, 26, 32, 33).  This is somewhat 
surprising in light of the similarity of experimental approaches used to support or to reject a role 
for either Erk3 catalytic activity or S189 phosphorylation.  The observation that Erk3 and Erk4 
can be detected in oligomers containing Prak may be sufficient to reconcile some of the previous 
discrepancies (34).  Nonetheless, the inability to selectively promote or inhibit atypical MAPK 
signaling remains a significant hurdle against a better understanding of Erk3 function and has led 
some to suggest that the ability of ERK3 mutants to activate MK5 depends on the experimental 
system applied (34).  
 
  Using high-density protein microarrays and recombinant Erk3 and Pak2 proteins we 
found that Erk3 is a Pak2 substrate in vitro.  Phospho-specific antibodies against residues within 
the Erk3 activation loop further indicated that serine 189 is a site phosphorylated by Pak2 in 
vitro. Additionally selective class I kinase inhibition led to a decrease in the extent of S189 
phosphorylation in HEK293 cells (Fig. A.6B) suggesting that this kinase substrate relationship 
between Pak and Erk3 is retained in vivo.  Specific inhibition of class I kinase activity in 
fibroblasts led to an increased nuclear retention of GFP-Erk3, suggesting a role for Paks in 
regulating the subcellular localization of Erk3.  This result was rather surprising as the Meloche 
laboratory had previously reported that nuclear export of Erk3 was independent of both 
activation loop phosphorylation and kinase activity in NIH3T3 cells (30), the same cell line used 
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in our studies.  The one obvious difference between the two approaches was the way in which 
Erk3 was detected; the Meloche group detected the localization of myc-tagged Erk3 by indirect 
immunofluorescence whereas we used GFP-Erk3.  We do not know whether this accounts for the 
observed differences, but GFP tagged variants of Erk3 have been used by other groups that 
display very similar subcellular localization in HEK293 cells as we observe in NIH3T3 cells 
(34). We also believe that the similarity in subcellular localization of the GFP-Erk3S189A 
variant to that seen for GFP-Erk3 in cells co-expressing mRFP-PID (Fig. A.5C,D) supports our 
conclusion that S189 phosphorylation modulates Erk3 subcellular localization. 
 
    Finally, as Erk3 S189 phosphorylation is required for the interaction with Prak, we 
further demonstrated that specific inhibition of Class I kinase activity in cells decreases the 
interaction between His6-Erk3 and endogenous Prak in HEK293 cells (Fig. A.6).   This effect 
was specific to the phosphorylation status of S189 as Prak interacted poorly with the Erk3S189A 
variant, whereas Prak interacted strongly with Erk3 phosphomimetic variant (S189D).  
Importantly, the interaction between Prak and Erk3S189D was insensitive to PID expression 
indicating that the ability of Pak to stabilize Erk3/Prak complexes derives exclusively from the 
ability to promote S189 phosphorylation. Collectively, our results are the first to demonstrate a 
relationship between the p21-activated kinases and Erk3 and further suggest a role for class I 
kinase activity in regulating atypical MAPK pathways by promoting S189 phosphorylation. 
 
  The specific consequences of atypical MAPK signaling are not well understood, but the 
biological importance of Erk3 is suggested from the following observations:  i) Expression of 
stabilized versions of Erk3 can promote cell cycle arrest in fibroblasts and Erk3 is stabilized and 
accumulates to high levels during muscle differentiation (24) ii) differential Erk3 expression is 
observed in many cancers including those harboring BRAFV600E mutations (35), iii) Erk3 is 
essential for neonatal development in mice (36).  An important question remains- how does S189 
phosphorylation promote the interaction with Prak?  Previous work has demonstrated that the 
residues of Erk3 required for Prak binding map to a region characterized by the sequence 
328FRIEDE333 (32) distinct from the common docking  (CD) domain used by classical ERK’s to 
bind to both their respective MAP2Ks and their cognate substrates (37).  Molecular modeling 
suggests that Erk4 S186 phosphorylation (analogous the Erk3 S189) might promote a 
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conformational change that increases the solvent accessibility of isoleucine 330 (within the 
conserved FRIEDE motif) allowing for efficient interaction with the C-terminal of Prak (32).  
 
   This is not the first time that Paks have been implicated in promoting the interaction of 
proteins functioning within a sequential kinase cascade.  Paks facilitate the interaction between 
Mek1 and Erk1/2 via phosphorylation of Mek1 S289 (13, 38). Unlike the situation for Erk3 
S189, S298 is not part of the Mek1 activation loop (consisting of serines 218 and 222) but is 
contained within the Mek1 proline rich sequence (residues 270 to 307).   Interestingly, the 
Catling laboratory has demonstrated that Pak-dependent phosphorylation of Mek1 on serine 298 
leads to an autocatalytic phosphorylation of the Mek1 activation loop residues and increased 
kinase activity against recombinant Erk1/2 in vitro (39).  Similar to Erk3 S189 phosphorylation, 
Mek1 S298 phosphorylation does not respond to growth factor stimulation (31, 39) but activated 
by cellular attachment signals (40).  To the best of our knowledge a role for cellular attachment 
in Erk3 S189 phosphorylation has never been addressed.  
 
 We believe that the identification of Paks as kinases responsible for Erk3 S189 
phosphorylation represents an important step forward in our understanding of atypical MAPK 
signaling cascades. Its identification affords the ability to modulate atypical MAPK signaling 
pathways in physiologically relevant settings by specific Pak inhibition.  In our opinion, use of 
the PID affords several important advantages over other experimental approaches, such as 
pharmacological inhibition or siRNA knockdowns. These advantages include, lack of isoform 
selectivity, high target specificity, lack of dominant negative effects and the ability to inhibit 
endogenous Class I activity in trans in tissue culture (31) and in transgenic animals (5).  Specific 
mutants of the PID (L107F) that no longer function as Pak inhibitors further provide an 
important control to evaluate the specific contribution of Pak kinase activity.  
 
   Even with the identification of Paks as S189 kinases, previous reports of the kinetics of 
S189 phosphorylation raise some important questions. As Erk3 S189 phosphorylation does not 
respond to signals that activate the classical MAPKs (19), S189 phosphorylation persists in 
HEK293 cells rendered quiescent by serum starvation (19).  Although the signals that activate 
Class I kinase activity differ from cell type to cell type, serum starvation is sufficient to reduce 
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Pak kinase activity in most cells as demonstrated by both Pak1 activation specific anti-sera as 
well as in-gel kinase assays (20, 31).  It is important to note that although we commonly think of 
Pak kinase activity being “off” in quiescent cells, this activity is still readily detected albeit as 
much lower levels than in cells stimulated with the appropriate growth factors.  As the relative 
levels of the inherently unstable Erk3 and Class I Paks are unknown, and likely to be cell type 
specific, basal Class I kinase activity may still be sufficient to promote S189 phosphorylation in 
quiescence cells.  
 
 Alternatively S189 could be targeted by kinases other than Pak.  Although entirely 
speculative, possible candidates include the group II Paks (Pak4, -5, -6), which are constitutively 
active kinases sharing similar substrate specificity with the class I Paks (28) or the related 
mammalian sterile 20-like kinase (Mst-1) as Erk3 was identified in a KSI protein microarray 
screen using recombinant Mst-1 (S. Jalan and J. Chernoff, unpublished observations).  It is 
important to note that although these proteins are all members of the Ste20 superfamily, neither 
the class II Paks nor Mst1 are inhibited by expression of the PID.     Irrespective of whether the 
ability to phosphorylate S189 is unique to Call I Paks, our results strongly suggest that Class I 
kinase activity is critical for the formation of Erk3/Prak complex in cells, and suggests and 
important role for Class I kinase activity in regulating atypical MAPK signaling. 
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